Transthyretin
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 4 PDB declaration: tetrameric（4） Consistent with protein copy count | Chain A； UniProt 1–147 Chain B； UniProt 1–147 | Mutation：V30M | MKT 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 BR BROMIDE ION × 16 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 5.8；293 K；20% PEG400, 0.092 M MES, 0.1 M KBr | Resolution 1.50 Å R-free 0.221 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 4Y9F | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1BM7 HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID) Deposited 1998-07-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | FLF 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.4；pH 7.4
|
Resolution 2.00 Å R-free 0.251 |
| 1BMZ HUMAN TRANSTHYRETIN (PREALBUMIN) Deposited 1998-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–143（114 aa）
Chain B
30–143（114 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.4；pH 7.4
|
Resolution 2.00 Å R-free 0.244 |
| 1BMZ HUMAN TRANSTHYRETIN (PREALBUMIN) Deposited 1998-07-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–143（114 aa）
Chain B
30–143（114 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.4；pH 7.4
|
Resolution 2.00 Å R-free 0.244 |
| 1BZ8 TRANSTHYRETIN (DEL VAL122) Deposited 1998-11-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：TRINUCLEOTIDE DELETION VARIANT DELVAL122 Mutation：TRINUCLEOTIDE DELETION VARIANT DELVAL122 | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.50
|
Resolution 2.00 Å R-free 0.277 |
| 1BZD TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1998-10-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：G6S Mutation：G6S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；PURIFIED PROTEIN (20MG/ML IN 25MM MONOBASIC SODIUM PHOSPHATE BUFFER, 0.15M NACL) WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.
|
Resolution 1.90 Å R-free 0.265 |
| 1BZE TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1998-10-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：M119T Mutation：M119T | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；PURIFIED PROTEIN (10MG/ML IN TRIS BUFFER, PH 7.5) WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.
|
Resolution 1.80 Å R-free 0.273 |
| 1DVQ CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN Deposited 2000-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–124（124 aa）
Chain B
1–124（124 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.223 |
| 1DVS CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH RESVERATROL Deposited 2000-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–124（124 aa）
Chain B
1–124（124 aa）
|
Not recorded | STL RESVERATROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.227 |
| 1DVT CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH FLURBIPROFEN Deposited 2000-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–124（124 aa）
Chain B
1–124（124 aa）
|
Not recorded | FLP FLURBIPROFEN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.220 |
| 1DVU CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DIBENZOFURAN-4,6-DICARBOXYLIC ACID Deposited 2000-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–124（124 aa）
Chain B
1–124（124 aa）
|
Not recorded | DBF DIBENZOFURAN-4,6-DICARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.220 |
| 1DVX CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DICLOFENAC Deposited 2000-01-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–124（124 aa）
Chain B
1–124（124 aa）
|
Not recorded | DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride
potassium phosphate
ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.215 |
| 1DVY CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICARBOXYLIC ACID Deposited 2000-01-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–124（124 aa）
Chain B
1–124（124 aa）
|
Not recorded | BPD N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.203 |
| 1DVZ CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACID Deposited 2000-01-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–124（124 aa）
Chain B
1–124（124 aa）
|
Not recorded | OFL O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride,
potassium phosphate,
ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.200 |
| 1E3F Structure of human transthyretin complexed with bromophenols: a new mode of binding Deposited 2000-06-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–145（125 aa）
Chain B
21–145（125 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.90 Å R-free 0.252 |
| 1E4H Structure of human transthyretin complexed with bromophenols: a new mode of binding Deposited 2000-07-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | GOL GLYCEROL × 4 PBR PENTABROMOPHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.80 Å R-free 0.235 |
| 1E5A Structure of human transthyretin complexed with bromophenols: a new mode of binding Deposited 2000-07-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | TBP 2,4,6-TRIBROMOPHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.80 Å R-free 0.262 |
| 1ETA THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain 1
21–147（127 aa）
Chain 2
21–147（127 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å |
| 1ETA THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
21–147（127 aa）
Chain 2
21–147（127 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å |
| 1ETB THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain 1
21–147（127 aa）
Chain 2
21–147（127 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å |
| 1ETB THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
21–147（127 aa）
Chain 2
21–147（127 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å |
| 1F41 CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN AT 1.5A RESOLUTION Deposited 2000-06-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；40% PEG 550MME, 0.1M HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
|
Resolution 1.30 Å R-free 0.216 |
| 1F86 TRANSTHYRETIN THR119MET PROTEIN STABILISATION Deposited 2000-06-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：THR119MET Mutation：THR119MET | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.9；277 K；sodium citrate, 1,2,3 heptanetriol, ammonium sulphate, glycerol, methanol, pH 4.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.10 Å R-free 0.177 |
| 1F86 TRANSTHYRETIN THR119MET PROTEIN STABILISATION Deposited 2000-06-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：THR119MET Mutation：THR119MET | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.9；277 K；sodium citrate, 1,2,3 heptanetriol, ammonium sulphate, glycerol, methanol, pH 4.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.10 Å R-free 0.177 |
| 1FH2 TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS Deposited 2000-07-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30M/T119M Mutation：V30M/T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.1；287 K；Ammonium Sulphate, Citrate Buffer, Glycerol, pH 5.1, VAPOR DIFFUSION, SITTING DROP, temperature 287K
|
Resolution 1.80 Å R-free 0.213 |
| 1FHN TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS Deposited 2000-08-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：T119M Mutation：T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.9；287 K；Ammonium Sulphate, Citrate Buffer, Glycerol, pH 4.9, VAPOR DIFFUSION, SITTING DROP, temperature 287K
|
Resolution 1.75 Å R-free 0.180 |
| 1G1O CRYSTAL STRUCTURE OF THE HIGHLY AMYLOIDOGENIC TRANSTHYRETIN MUTANT TTR G53S/E54D/L55S Deposited 2000-10-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；PEG 5000 MME, sodium citrate, ammonium sulphate, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.290 |
| 1GKO An Engineered Transthyretin Monomer that is Non-amyloidogenic - Unless Partially Denatured Deposited 2001-08-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 8.8；0.2 M MGCL2, 0.1 M TRIS BUFFER, PH 8.5, 30% W/V POLYETHYLENE GLYCOL 4000
|
Resolution 2.10 Å R-free 0.269 |
| 1ICT MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4) Deposited 2001-04-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
HANGMAN HANGING DROP CRYSTALLIZATION METHOD；pH 4.9；293 K；55% AMMONIUM SULFATE; 0.1 M PHOSPHATE BUFFER, pH 4.9, HANGMAN HANGING DROP CRYSTALLIZATION METHOD, temperature 293K
|
Resolution 3.00 Å R-free 0.289 |
| 1ICT MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4) Deposited 2001-04-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
Chain G
21–147（127 aa）
Chain H
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
HANGMAN HANGING DROP CRYSTALLIZATION METHOD；pH 4.9；293 K；55% AMMONIUM SULFATE; 0.1 M PHOSPHATE BUFFER, pH 4.9, HANGMAN HANGING DROP CRYSTALLIZATION METHOD, temperature 293K
|
Resolution 3.00 Å R-free 0.289 |
| 1III CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT ROOM TEMPERATURE Deposited 2001-04-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：TRANSTHYRETIN
Chain B
21–147（127 aa）
Fragment：TRANSTHYRETIN
|
Mutation：Y114C Mutation：Y114C | BME BETA-MERCAPTOETHANOL × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；2M ammonium sulphate, 0.1M sodium citrate, 2% PEG 200, 1% BME, pH 5.0,
VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
|
Resolution 2.00 Å R-free 0.235 |
| 1IIK CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT CRYO TEMPERATURE Deposited 2001-04-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：TRANSTHYRETIN
Chain B
21–147（127 aa）
Fragment：TRANSTHYRETIN
|
Mutation：Y114C Mutation：Y114C | BME BETA-MERCAPTOETHANOL × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；40% PEG 550 monomethyl ether, 0.1M sodium citrate, 0.1M ammonium sulphate, 0.1% BME,
pH 5.0, VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
|
Resolution 2.00 Å R-free 0.239 |
| 1IJN Crystal structure of the transthyretin mutant TTR C10A/Y114C Deposited 2001-04-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：TRANSTHYRETIN
Chain B
21–147（127 aa）
Fragment：TRANSTHYRETIN
|
Mutation：C10A/Y114C Mutation：C10A/Y114C | BME BETA-MERCAPTOETHANOL × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；40% PEG 550 monomethyl ether, 0.1M sodium citrate, 0.1M ammonium sulphate, 0.1% BME,
pH 5.0, VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
|
Resolution 1.70 Å R-free 0.237 |
| 1IJN Crystal structure of the transthyretin mutant TTR C10A/Y114C Deposited 2001-04-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Fragment：TRANSTHYRETIN
Chain B
21–147（127 aa）
Fragment：TRANSTHYRETIN
|
Mutation：C10A/Y114C Mutation：C10A/Y114C | BME BETA-MERCAPTOETHANOL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；40% PEG 550 monomethyl ether, 0.1M sodium citrate, 0.1M ammonium sulphate, 0.1% BME,
pH 5.0, VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
|
Resolution 1.70 Å R-free 0.237 |
| 1QAB The structure of human retinol binding protein with its carrier protein transthyretin reveals interaction with the carboxy terminus of RBP Deposited 1999-02-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | RTL RETINOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.20 Å R-free 0.403 |
| 1QWH a covalent dimer of transthyretin that affects the amyloid pathway Deposited 2003-09-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–147（117 aa）
Chain B
31–147（117 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.8；298 K；PEG 4000, 0.2 M Magnesium Nitrate , pH 5.8, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.36 Å R-free 0.222 |
| 1RLB RETINOL BINDING PROTEIN COMPLEXED WITH TRANSTHYRETIN Deposited 1995-02-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
1–127（127 aa）
Chain B
1–127（127 aa）
Chain C
1–127（127 aa）
Chain D
1–127（127 aa）
|
Not recorded | REA RETINOIC ACID × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å |
| 1SOK Crystal structure of the transthyretin mutant A108Y/L110E solved in space group p21212 Deposited 2004-03-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A108Y, L110E Mutation：A108Y, L110E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6；291 K；Tris, peg550mme, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
|
Resolution 1.60 Å R-free 0.242 |
| 1SOQ Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2 Deposited 2004-03-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A108Y, L110E Mutation：A108Y, L110E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6；291 K；Tris, PEG550MME, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
|
Resolution 2.10 Å R-free 0.246 |
| 1SOQ Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2 Deposited 2004-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：A108Y, L110E Mutation：A108Y, L110E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6；291 K；Tris, PEG550MME, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
|
Resolution 2.10 Å R-free 0.246 |
| 1SOQ Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2 Deposited 2004-03-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：A108Y, L110E Mutation：A108Y, L110E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6；291 K；Tris, PEG550MME, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
|
Resolution 2.10 Å R-free 0.246 |
| 1THA MECHANISM OF MOLECULAR RECOGNITION. STRUCTURAL ASPECTS OF 3,3'-DIIODO-L-THYRONINE BINDING TO HUMAN SERUM TRANSTHYRETIN Deposited 1991-11-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–127（127 aa）
Chain B
1–127（127 aa）
|
Not recorded | T33 3,3'-DEIODO-THYROXINE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å |
| 1THC CRYSTAL STRUCTURE DETERMINATION AT 2.3A OF HUMAN TRANSTHYRETIN-3',5'-DIBROMO-2',4,4',6-TETRA-HYDROXYAURONE COMPLEX Deposited 1992-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–127（127 aa）
Chain B
1–127（127 aa）
|
Not recorded | FL9 3',5'-DIBROMO-2',4,4',6'-TETRAHYDROXY AURONE × 8 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1TLM STRUCTURAL ASPECTS OF INOTROPIC BIPYRIDINE BINDING: CRYSTAL STRUCTURE DETERMINATION TO 1.9 ANGSTROMS OF THE HUMAN SERUM TRANSTHYRETIN-MILRINONE COMPLEX Deposited 1992-12-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–127（127 aa）
Chain B
1–127（127 aa）
|
Not recorded | MIL MILRINONE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TSH TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1996-10-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：VARIANT A60T Mutation：VARIANT A60T | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；PURIFIED PROTEIN (20MG/ML IN 25MM MONOBASIC SODIUM PHOSPHATE BUFFER, 0.15M NACL) WAS CRYSTALLIZED FROM 2.5M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.
|
Resolution 1.70 Å R-free 0.248 |
| 1TT6 The orthorhombic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-06-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SO4 SULFATE ION × 2 DES DIETHYLSTILBESTROL × 4 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.80 Å R-free 0.218 |
| 1TTA THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1992-11-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å |
| 1TTB THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1992-11-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å |
| 1TTC THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1992-11-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å |
| 1TTR TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANT Deposited 1996-04-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V122I Mutation：V122I | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.3；pH 5.3
|
Resolution 1.90 Å |
| 1TTR TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANT Deposited 1996-04-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V122I Mutation：V122I | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.3；pH 5.3
|
Resolution 1.90 Å |
| 1TYR TRANSTHYRETIN COMPLEX WITH RETINOIC ACID Deposited 1995-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 9CR (9cis)-retinoic acid × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å |
| 1TYR TRANSTHYRETIN COMPLEX WITH RETINOIC ACID Deposited 1995-05-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 9CR (9cis)-retinoic acid × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å |
| 1TZ8 The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-07-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | ACT ACETATE ION × 2 DMS DIMETHYL SULFOXIDE × 2 GOL GLYCEROL × 2 DES DIETHYLSTILBESTROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.85 Å R-free 0.221 |
| 1TZ8 The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-07-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | GOL GLYCEROL × 1 DES DIETHYLSTILBESTROL × 2 CO3 CARBONATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.85 Å R-free 0.221 |
| 1TZ8 The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-07-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | GOL GLYCEROL × 2 DES DIETHYLSTILBESTROL × 4 CO3 CARBONATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.85 Å R-free 0.221 |
| 1U21 transthyretin with tethered inhibitor on one monomer. Deposited 2004-07-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | P2C 2-[(3,5-DICHLORO-4-TRIOXIDANYLPHENYL)AMINO]BENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；PEG 4000, calcium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.69 Å R-free 0.239 |
| 1X7S The X-ray crystallographic structure of the amyloidogenic variant TTR Tyr78Phe Deposited 2004-08-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：Y78F Mutation：Y78F | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.8；287 K；Ammonium Sulfate, Glycerol, Sodium Acetate, pH 4.8, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.55 Å R-free 0.238 |
| 1X7T Structure of TTR R104H: a non-amyloidogenic variant with protective clinical effects Deposited 2004-08-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：R104H Mutation：R104H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.1；287 K；Ammonium Sulfate, Glycerol, Sodium Acetate, pH 5.1, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.60 Å R-free 0.252 |
| 1Y1D Crystal structure of transthyretin in complex with iododiflunisal Deposited 2004-11-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | FHI 2',4'-DIFLUORO-4-HYDROXY-5-IODO-1,1'-BIPHENYL-3-CARBOXYLIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；287 K；0.2M sodium citrate, 2.4M ammonium sulfate, 6% glycerol, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.70 Å R-free 0.222 |
| 1Z7J Human transthyretin (also called prealbumin) complex with 3, 3',5,5'-tetraiodothyroacetic acid (t4ac) Deposited 2005-03-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | T4A 3,3',5,5'-TETRAIODOTHYROACETIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；48% ammonium sulfate, 0.l M phosphate buffer, pH 5.50, VAPOR DIFFUSION, HANGING DROP, temperature 4.0K
|
Resolution 2.20 Å R-free 0.217 |
| 1ZCR Crystal structure of human Transthyretin with bound iodide Deposited 2005-04-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IOD IODIDE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；291 K；Ammonium sulphate, 0.4M NaI, sodium citrate, PEG 200, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.80 Å R-free 0.238 |
| 1ZD6 Crystal structure of human transthyretin with bound chloride Deposited 2005-04-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CL CHLORIDE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；291 K；ammonium sulphate, sodium citrate, polyethyleneglycol, sodium chloride, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.90 Å R-free 0.221 |
| 2B14 The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Leu 55 Pro Deposited 2005-09-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：L55P Mutation：L55P | DNF 2,4-DINITROPHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；287 K；PEG550, Hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 2.00 Å R-free 0.239 |
| 2B15 The crystal structure of 2,4-dinitrophenol in complex with human transthyretin Deposited 2005-09-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SO4 SULFATE ION × 4 DNF 2,4-DINITROPHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.8；287 K；ammonium sulfate, glycerol, sodium acetate, pH 4.8, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.70 Å R-free 0.218 |
| 2B16 The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Tyr78Phe Deposited 2005-09-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：Y78F Mutation：Y78F | DNF 2,4-DINITROPHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Ammonium Sulfate, glycerol, sodium acetate, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.75 Å R-free 0.236 |
| 2B77 Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID Deposited 2005-10-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 3CA 2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；1 mM EDTA, 10 mM sodium phosphate, 0.35-0.50 M ammonium sulfate - crystals were soaked with the inhibitor, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å R-free 0.238 |
| 2B9A Human transthyretin (TTR) complexed with diflunisal analogues- TTR.3',5'-difluorobiphenyl-4-carboxylic acid Deposited 2005-10-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | FBC 3',5'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；ammonium sulfate, 100 mM KCL, 1 mM EDTA, 10 mM sodium phosphate, soaked with the inhibitor, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.54 Å R-free 0.246 |
| 2F7I Human transthyretin (TTR) complexed with diflunisal analogues- TTR. 2',6'-Difluorobiphenyl-4-carboxylic Acid Deposited 2005-11-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 26C 2',6'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；AMMONIUM SULFATE, 100 MM KCL, 1 MM EDTA, 10 MM SODIUM PHOSPHATE, SOAKED WITH THE INHIBITOR, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.252 |
| 2F8I Human transthyretin (TTR) complexed with Benzoxazole Deposited 2005-12-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 205 2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；1 MM EDTA, 100 mM KCL, 10 MM SODIUM R 0.35 M AMMONIUM SULFATE - CRYSTALS WERE SOAKED WITH THE INHIBITOR, PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K, pH 7.00
|
Resolution 1.54 Å R-free 0.246 |
| 2F8I Human transthyretin (TTR) complexed with Benzoxazole Deposited 2005-12-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 205 2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；1 MM EDTA, 100 mM KCL, 10 MM SODIUM R 0.35 M AMMONIUM SULFATE - CRYSTALS WERE SOAKED WITH THE INHIBITOR, PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K, pH 7.00
|
Resolution 1.54 Å R-free 0.246 |
| 2FBR Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (4 carbon linker) Deposited 2005-12-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 44C 4'-(4-{4-[(2-CARBOXYPHENYL)AMINO]PHENOXY}BUTOXY)-1,1'-BIPHENYL-4-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；TTR bivalent inhibitor complexes of 1:1 stoichiometry resulting from coassembly at 5-7 mg/mL (95-133 microM in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, 0.35-0.50 M ammonium sulfate equilibrated against 2 M ammonium sulfate, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.46 Å R-free 0.224 |
| 2FLM Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (6 carbon linker) Deposited 2006-01-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 6CA 4'-{6-[4-(2-CARBOXYPHENYLAMINO)-PHENOXY]-HEXYLOXY}-BIPHENYL-4-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；pH 7.00, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.65 Å R-free 0.234 |
| 2G3X Crystal structure of Transthyretin mutant I84S at acidic pH Deposited 2006-02-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：I84S Mutation：I84S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；15% PEG monomethyl ether, 0.1M ammonium sulphate, 50mM sodium acetate pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.58 Å R-free 0.241 |
| 2G3Z Crystal structure of Transthyretin mutant I84A at low pH Deposited 2006-02-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：I84A Mutation：I84A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；15% PEG monomethyl ether, 0.1M ammonium sulphate, 50mM sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.90 Å R-free 0.245 |
| 2G4E Crystal structure of transthyretin mutant I84A at neutral pH Deposited 2006-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：I84A Mutation：I84A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1M CaCl2, 14% PEG 400, 7.5% PEG 1500, 0.05M sodium Hepes, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.17 Å R-free 0.246 |
| 2G4G Crystal structure of human transthyretin at pH 4.6 Deposited 2006-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；15% PEG monomethyl ether, 0.1M ammonium sulphate, 50mM sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.85 Å R-free 0.233 |
| 2G5U Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4,4'-dihydroxy-3,3',5,5'-tetrachlorobiphenyl Deposited 2006-02-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | PCQ 3,5,3',5'-TETRACHLORO-BIPHENYL-4,4'-DIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；Crystals of recombinant WT TTR were obtained from protein solutions at 5 mg/ml (in 100 mM KCl, 100 mM phosphate [pH 7.4], 1 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drop experiments. The TTR ligand complexes were prepared from crystals soaked for 2 weeks with a 10-fold molar excess , pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.80 Å R-free 0.220 |
| 2G9K Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-2',3,3',4',5-Pentachlorobiphenyl Deposited 2006-03-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | NE1 2',3,3',4',5-PENTACHLOROBIPHENYL-4-OL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；CRYSTALLIZATION CONDITIONS: CRYSTALS OF RECOMBINANT WT TTR WERE
OBTAINED FROM PROTEIN SOLUTIONS AT 5 MG/ML (IN 100 MM KCL, 100
MM PHOSPHATE [PH 7.4], 1 M AMMONIUM SULFATE) EQUILIBRATED
AGAINST 2 M AMMONIUM SULFATE IN HANGING DROP EXPERIMENTS. THE
TTR LIGAND COMPLEXES WERE PREPARED FROM CRYSTALS SOAKED FOR 2
WEEKS WITH A 10-FOLD MOLAR EXCESS , pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.85 Å R-free 0.257 |
| 2GAB Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-3,3',5,4'-tetrachlorobiphenyl Deposited 2006-03-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | NE2 3,3',4',5-TETRACHLOROBIPHENYL-4-OL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；CRYSTALLIZATION CONDITIONS: CRYSTALS OF RECOMBINANT WT TTR WERE
OBTAINED FROM PROTEIN SOLUTIONS AT 5 MG/ML (IN 100 MM KCL, 100
MM PHOSPHATE [PH 7.4], 1 M AMMONIUM SULFATE) EQUILIBRATED
AGAINST 2 M AMMONIUM SULFATE IN HANGING DROP EXPERIMENTS. THE
TTR LIGAND COMPLEXES WERE PREPARED FROM CRYSTALS SOAKED FOR 2
WEEKS WITH A 10-FOLD MOLAR EXCESS , PH 7.00, VAPOR DIFFUSION,
HANGING DROP, TEMPERATURE 298K , VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.85 Å R-free 0.238 |
| 2H4E Crystal structure of Cys10 sulfonated transthyretin Deposited 2006-05-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；0.2M sodium acetate, 2.0 M ammonium sulphate, 6 % glycerol, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.45 Å R-free 0.198 |
| 2M5N Atomic-resolution structure of a cross-beta protofilament Deposited 2013-02-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 16 PDB declaration: hexadecameric |
Chain A
125–135（11 aa）
Fragment：UNP residues 125-135
Chain B
125–135（11 aa）
Fragment：UNP residues 125-135
Chain C
125–135（11 aa）
Fragment：UNP residues 125-135
Chain D
125–135（11 aa）
Fragment：UNP residues 125-135
Chain E
125–135（11 aa）
Fragment：UNP residues 125-135
Chain F
125–135（11 aa）
Fragment：UNP residues 125-135
Chain G
125–135（11 aa）
Fragment：UNP residues 125-135
Chain H
125–135（11 aa）
Fragment：UNP residues 125-135
Chain I
125–135（11 aa）
Fragment：UNP residues 125-135
Chain J
125–135（11 aa）
Fragment：UNP residues 125-135
Chain K
125–135（11 aa）
Fragment：UNP residues 125-135
Chain L
125–135（11 aa）
Fragment：UNP residues 125-135
Chain M
125–135（11 aa）
Fragment：UNP residues 125-135
Chain N
125–135（11 aa）
Fragment：UNP residues 125-135
Chain O
125–135（11 aa）
Fragment：UNP residues 125-135
Chain P
125–135（11 aa）
Fragment：UNP residues 125-135
|
Not recorded | No recorded non-water small molecule |
SOLID-STATE NMR
NMR measurement conditions
pH 2；Pressure ambient
NMR sample composition
15 mg/mL [U-100% 13C; U-100% 15N] TTR(105-115), 10% acetonitrile/water solution | 10% acetonitrile/water solution
|
Resolution not provided |
| 2NBO Solution structure of the F87M/L110M variant of transthyretin in the monomeric state Deposited 2016-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
21–147（127 aa）
|
Mutation：F107M, L130M | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 50
NMR sample composition
0.3-0.7 mM [U-13C; U-15N] M-TTR, 50 mM MES, 100 mM sodium chloride, 5 mM DTT, 0.1 mM DSS, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.7 mM [U-13C; U-15N] M-TTR, 50 mM MES, 100 mM sodium chloride, 5 mM DTT, 0.1 mM DSS, 100% D2O | 100% D2O
|
Resolution not provided |
| 2NBP Solution structure of the T119M variant of transthyretin in its monomeric state Deposited 2016-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
21–147（127 aa）
|
Mutation：F107M, L130M, T139M | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure ambient
NMR sample composition
0.6-1.2 mM [U-13C; U-15N] T119M M-TTR, 50 mM MES, 100 mM sodium chloride, 5 mM DTT, 0.1 mM DSS, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2NOY Crystal structure of transthyretin mutant I84S at PH 7.5 Deposited 2006-10-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：I84S Mutation：I84S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.1M CaCl2, 14%(w/v) PEG 400, 7.5%(w/v) PEG 1500, 0.05M sodium Hepes (pH 7.5), VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.80 Å R-free 0.251 |
| 2PAB STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFINEMENT AT 1.8 ANGSTROMS Deposited 1977-09-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–127（127 aa）
Chain B
1–127（127 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å |
| 2PAB STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFINEMENT AT 1.8 ANGSTROMS Deposited 1977-09-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–127（127 aa）
Chain B
1–127（127 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.80 Å |
| 2QEL Crystal structure of the highly amyloidogenic transthyretin mutant TTR G53S/E54D/L55S- heated protein Deposited 2007-06-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1M Tris, 2.4M Ammonium sulphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.29 Å R-free 0.289 |
| 2QGB Human transthyretin (TTR) in Apo-form Deposited 2007-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 1.40 Å R-free 0.188 |
| 2QGC Human transthyretin (TTR) complexed with 2-(3,5-Dimethyl-4-hydroxyphenyl)benzoxazole Deposited 2007-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | MR4 4-(1,3-BENZOXAZOL-2-YL)-2,6-DIMETHYLPHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 1.30 Å R-free 0.174 |
| 2QGD Human transthyretin (TTR) complexed with 2-(3,5-Dibromo-4-hydroxyphenyl)benzoxazole Deposited 2007-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | MR5 4-(1,3-BENZOXAZOL-2-YL)-2,6-DIBROMOPHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 1.50 Å R-free 0.199 |
| 2QGE Human transthyretin (TTR) complexed with 2-(3,5-Dimethylphenyl)benzoxazole Deposited 2007-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | MR6 2-(3,5-DIMETHYLPHENYL)-1,3-BENZOXAZOLE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 1.45 Å R-free 0.200 |
| 2ROX TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH THYROXINE (T4) Deposited 1996-10-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SO4 SULFATE ION × 2 T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å |
| 2ROY TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH 3',5'-DINITRO-N-ACETYL-L-THYRONINE Deposited 1996-10-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | P28 3',5'-DINITRO-N-ACETYL-L-THYRONINE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å |
| 2TRH TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1996-10-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：VARIANT R10C Mutation：VARIANT R10C | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；PURIFIED PROTEIN (20MG/ML IN 100MM TRIS BUFFER, PH 7.5) WAS CRYSTALLIZED FROM\\ 2.25M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.\\, pH 6.5
|
Resolution 1.90 Å R-free 0.299 |
| 2TRY TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1996-10-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：VARIANT S77Y Mutation：VARIANT S77Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；PURIFIED PROTEIN (25MG/ML IN 100MM TRIS BUFFER, PH 7.5) WAS CRYSTALLIZED FROM 1.5M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5, AT ROOM TEMPERATURE., pH 6.5
|
Resolution 2.00 Å R-free 0.310 |
| 2WQA Complex of TTR and RBP4 and Oleic Acid Deposited 2009-08-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | SO4 SULFATE ION × 11 OLA OLEIC ACID × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.85 Å R-free 0.253 |
| 3A4D Crystal structure of Human Transthyretin (wild-type) Deposited 2009-07-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SO4 SULFATE ION × 4 GOL GLYCEROL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；200mM citrate, 3M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.229 |
| 3A4E Crystal structure of Human Transthyretin (E54G) Deposited 2009-07-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | GOL GLYCEROL × 6 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；200 mM citrate, 3M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.238 |
| 3A4F Crystal Structure of Human Transthyretin (E54K) Deposited 2009-07-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | GOL GLYCEROL × 10 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；200mM citrate, 3M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.99 Å R-free 0.223 |
| 3B56 Crystal structure of transthyretin in complex with 3,5-diiodosalicylic acid Deposited 2007-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | DIU 2-HYDROXY-3,5-DIIODO-BENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；287 K；200mM acetate buffer, 2.2M ammonium sulfate, 7% glycerol, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.55 Å R-free 0.214 |
| 3BSZ Crystal structure of the transthyretin-retinol binding protein-Fab complex Deposited 2007-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | RTL RETINOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；295 K；2.35M ammonium phosphate, 10mM sodium citrate, 10mM beta-mercaptoethanol, pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 295K
|
Resolution 3.38 Å R-free 0.312 |
| 3BT0 Crystal structure of transthyretin variant V20S Deposited 2007-12-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V20S Mutation：V20S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；295 K；0.066M CaCl2, 19% (w/v) PEG 400, 0.13M sodium Hepes , pH 7.5, VAPOR DIFFUSION, temperature 295K
|
Resolution 1.59 Å R-free 0.229 |
| 3CBR Crystal structure of human Transthyretin (TTR) at pH3.5 Deposited 2008-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3.5；289 K；5-7 mg/ml protein, 0.1 M sodium acetate, 20 % PEG 3350, 0.3-0.5 M ammonium sulfate equilibrated against 2.0M ammonium sulfate, pH 3.5, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.70 Å R-free 0.260 |
| 3CFM Crystal structure of the apo form of human wild-type transthyretin Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–147（118 aa）
Fragment：UNP residue 30-147
Chain B
30–147（118 aa）
Fragment：UNP residue 30-147
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；Mother liquor: 100 mM tris pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop 1 uL mother liquor + 1 uL TTR 10 mg/mL; crystals appeared in about 5 days, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.60 Å R-free 0.218 |
| 3CFM Crystal structure of the apo form of human wild-type transthyretin Deposited 2008-03-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–147（118 aa）
Fragment：UNP residue 30-147
Chain B
30–147（118 aa）
Fragment：UNP residue 30-147
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；Mother liquor: 100 mM tris pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop 1 uL mother liquor + 1 uL TTR 10 mg/mL; crystals appeared in about 5 days, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.60 Å R-free 0.218 |
| 3CFN Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonate Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–147（118 aa）
Fragment：UNP residue 30-147
Chain B
30–147（118 aa）
Fragment：UNP residue 30-147
|
Not recorded | 2AN 8-ANILINO-1-NAPHTHALENE SULFONATE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop consisting of 1 uL mother liquor and 1 uL wtTTR 10 mg/mL; crystals appeared in about 5 days; complex obtained by soaking in mother liquor supplemented with saturating amount of ligand., VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.87 Å R-free 0.245 |
| 3CFN Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonate Deposited 2008-03-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–147（118 aa）
Fragment：UNP residue 30-147
Chain B
30–147（118 aa）
Fragment：UNP residue 30-147
|
Not recorded | 2AN 8-ANILINO-1-NAPHTHALENE SULFONATE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop consisting of 1 uL mother liquor and 1 uL wtTTR 10 mg/mL; crystals appeared in about 5 days; complex obtained by soaking in mother liquor supplemented with saturating amount of ligand., VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.87 Å R-free 0.245 |
| 3CFQ Crystal structure of human wild-type transthyretin in complex with diclofenac Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–147（118 aa）
Fragment：UNP residues 30-147
Chain B
30–147（118 aa）
Fragment：UNP residues 30-147
|
Not recorded | DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH7.5, 100 mM KCl, 20 % v/v PEG400; drop: 1 uL mother liquor + 1 uL wtTTR 10 mg/mL; crystals appeared in 5 days; complexes obtained by soaking in mother liquor supplemented with saturating amount of diclofenac, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.09 Å R-free 0.249 |
| 3CFQ Crystal structure of human wild-type transthyretin in complex with diclofenac Deposited 2008-03-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–147（118 aa）
Fragment：UNP residues 30-147
Chain B
30–147（118 aa）
Fragment：UNP residues 30-147
|
Not recorded | DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH7.5, 100 mM KCl, 20 % v/v PEG400; drop: 1 uL mother liquor + 1 uL wtTTR 10 mg/mL; crystals appeared in 5 days; complexes obtained by soaking in mother liquor supplemented with saturating amount of diclofenac, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.09 Å R-free 0.249 |
| 3CFT Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonate Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–147（118 aa）
Fragment：UNP residues 30-147
Chain B
30–147（118 aa）
Fragment：UNP residues 30-147
|
Not recorded | 5NS 5-aminonaphthalene-1-sulfonic acid × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.87 Å R-free 0.239 |
| 3CFT Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonate Deposited 2008-03-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–147（118 aa）
Fragment：UNP residues 30-147
Chain B
30–147（118 aa）
Fragment：UNP residues 30-147
|
Not recorded | 5NS 5-aminonaphthalene-1-sulfonic acid × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.87 Å R-free 0.239 |
| 3CN0 Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbene Deposited 2008-03-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ1 2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6
and co-crystallized at room temperature using the vapor diffusion sitting
drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol
at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M
sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.52 Å R-free 0.189 |
| 3CN0 Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbene Deposited 2008-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ1 2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6
and co-crystallized at room temperature using the vapor diffusion sitting
drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol
at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M
sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.52 Å R-free 0.189 |
| 3CN1 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbene Deposited 2008-03-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ2 2,6-dibromo-4-[(E)-2-phenylethenyl]phenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were
frozen using a cryo-protectant solution of 1.395 M sodium citrate,
pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.52 Å R-free 0.188 |
| 3CN1 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbene Deposited 2008-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ2 2,6-dibromo-4-[(E)-2-phenylethenyl]phenol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were
frozen using a cryo-protectant solution of 1.395 M sodium citrate,
pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.52 Å R-free 0.188 |
| 3CN2 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenyl Deposited 2008-03-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ3 3,5-dibromobiphenyl-4-ol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were
frozen using a cryo-protectant solution of 1.395 M sodium citrate,
pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.52 Å R-free 0.197 |
| 3CN2 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenyl Deposited 2008-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ3 3,5-dibromobiphenyl-4-ol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were
frozen using a cryo-protectant solution of 1.395 M sodium citrate,
pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.52 Å R-free 0.197 |
| 3CN3 Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene Deposited 2008-03-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ4 2,6-dibromo-4-phenoxyphenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were
frozen using a cryo-protectant solution of 1.395 M sodium citrate,
pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.80 Å R-free 0.216 |
| 3CN3 Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene Deposited 2008-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ4 2,6-dibromo-4-phenoxyphenol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were
frozen using a cryo-protectant solution of 1.395 M sodium citrate,
pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.80 Å R-free 0.216 |
| 3CN4 Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamide Deposited 2008-03-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ5 N-(3,5-dibromo-4-hydroxyphenyl)benzamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen
using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5,
containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.40 Å R-free 0.202 |
| 3CN4 Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamide Deposited 2008-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LJ5 N-(3,5-dibromo-4-hydroxyphenyl)benzamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl,
at pH 7.6 and co-crystallized at room temperature using the vapor
diffusion sitting drop method. Crystals were grown from 1.395 M
sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen
using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5,
containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP,
temperature 298.0K
|
Resolution 1.40 Å R-free 0.202 |
| 3CXF Crystal structure of transthyretin variant Y114H Deposited 2008-04-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：Y114H Mutation：Y114H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；295 K；0.066M CaCl2, 19 % (w/v) PEG 400, 0.13M sodium Hepes, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
Resolution 2.30 Å R-free 0.281 |
| 3CXF Crystal structure of transthyretin variant Y114H Deposited 2008-04-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：Y114H Mutation：Y114H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；295 K；0.066M CaCl2, 19 % (w/v) PEG 400, 0.13M sodium Hepes, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
Resolution 2.30 Å R-free 0.281 |
| 3D2T Human transthyretin (ttr) complexed with diflunisal Deposited 2008-05-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；5-7 mg/ml protein, in 0.3 M AMMONIUM SULFATE, 100 MM KCL, 1 MM EDTA, 10 MM SODIUM PHOSPHATE equilibrated against 2 M ammonium sulfate; SOAKED WITH THE INHIBITOR., pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.85 Å R-free 0.235 |
| 3D7P Crystal structure of human Transthyretin (TTR) at pH 4.0 Deposited 2008-05-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；289 K；TTR pH 4.0 crystals were grown in the presence of 0.1 M sodium acetate (pH 4.0), 100 mM KCl, 1 mM EDTA and 0.3-0.5 M ammonium sulfate which was equilibrated against 2 M ammonium sulfate in hanging drop, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.72 Å R-free 0.249 |
| 3DGD Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 Deposited 2008-06-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：Y Mutation：Y Mutation：Y Mutation：Y | ZN ZINC ION × 15 ACT ACETATE ION × 12 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 4,6; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, PH 4.6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K, pH 4.60
|
Resolution 1.38 Å R-free 0.202 |
| 3DID Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 soaked Deposited 2008-06-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：Y Mutation：Y Mutation：Y Mutation：Y | ZN ZINC ION × 12 ACT ACETATE ION × 6 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 4,6; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, pH 4.60, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.78 Å R-free 0.242 |
| 3DJR CRYSTAL STRUCTURE OF TRANSTHYRETIN VARIANT L58H at neutral pH Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：L58H Mutation：L58H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；295 K；32% PEG 400, 0.05-0.2M CaCl2, 0.1M NaHepes, pH 7.5, VAPOR DIFFUSION, temperature 295K
|
Resolution 2.02 Å R-free 0.228 |
| 3DJS Crystal structure of transthyretin variant L58H at acidic pH Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：L58H Mutation：L58H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.6；295 K；32% PEG 2000, 0.1M NaAc, 0.2M Am2SO4 , pH 4.6, VAPOR DIFFUSION, temperature 295K
|
Resolution 1.80 Å R-free 0.217 |
| 3DJT Crystal structure of transthyretin variant V30M at acidic pH Deposited 2008-06-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.6；295 K；32% PEG 2000, 0.1M NaAc, 0.2M Am2SO4
, pH 4.6, VAPOR DIFFUSION, temperature 295K
|
Resolution 2.30 Å R-free 0.253 |
| 3DJZ Crystal structure of transthyretin variant L55P at neutral pH Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：L55P Mutation：L55P | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；295 K；32% PEG 400, 0.05-0.2M CaCl2, 0.1M NaHepes , pH 7.5, VAPOR DIFFUSION, temperature 295K
|
Resolution 1.82 Å R-free 0.219 |
| 3DK0 Crystal structure of transthyretin variant L55P at acidic pH Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：L55P Mutation：L55P | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.6；295 K；32% PEG 400, 0.05-0.2M CaCl2, 0.1M NaHepes , pH 4.6, VAPOR DIFFUSION, temperature 295K
|
Resolution 1.87 Å R-free 0.223 |
| 3DK2 Crystal structure of transthyretin variant Y114H at acidic pH Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：Y114H Mutation：Y114H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.6；295 K；Na Citrate 0.1 M, Ammonium sulfate 2M , pH 4.6, VAPOR DIFFUSION, temperature 295K
|
Resolution 2.35 Å R-free 0.247 |
| 3DO4 Crystal structure of transthyretin variant T60A at acidic pH Deposited 2008-07-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain D
21–147（127 aa）
Chain F
21–147（127 aa）
Chain G
21–147（127 aa）
Chain H
21–147（127 aa）
|
Mutation：T60A Mutation：T60A Mutation：T60A Mutation：T60A | ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.6；298 K；15% PEG 4000, 0.05M NaAcetate, 0.1M AmmoniumAcetate , pH 4.6, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.40 Å R-free 0.267 |
| 3DO4 Crystal structure of transthyretin variant T60A at acidic pH Deposited 2008-07-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain E
21–147（127 aa）
|
Mutation：T60A Mutation：T60A Mutation：T60A Mutation：T60A | ACT ACETATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.6；298 K；15% PEG 4000, 0.05M NaAcetate, 0.1M AmmoniumAcetate , pH 4.6, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.40 Å R-free 0.267 |
| 3ESN Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide Deposited 2008-10-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | DZ1 N-(3,5-dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.35 Å R-free 0.202 |
| 3ESO Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,5-dichlorobenzamide Deposited 2008-10-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | DZ2 2,5-dichloro-N-(3,5-dibromo-4-hydroxyphenyl)benzamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.31 Å R-free 0.204 |
| 3ESP Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-3,5-dimethyl-4-hydroxybenzamide Deposited 2008-10-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | DZ3 N-(3,5-dibromo-4-hydroxyphenyl)-4-hydroxy-3,5-dimethylbenzamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.31 Å R-free 0.201 |
| 3FC8 Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOMe Deposited 2008-11-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–144（124 aa）
Chain B
21–144（124 aa）
|
Not recorded | IFA METHYL N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINATE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；287 K；2.0 M ammonium sulfate, 7% glycerol and 0.2 M sodium acetate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.85 Å R-free 0.210 |
| 3FCB Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH Deposited 2008-11-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–144（124 aa）
Chain B
21–144（124 aa）
|
Not recorded | IFB N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；2.2 M ammonium sulphate, 7% glycerol and 0.2 M sodium acetate, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 1.80 Å R-free 0.226 |
| 3GLZ Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic acid (inhibitor 11) Deposited 2009-03-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 1BD 3-[({(1E)-[2-(trifluoromethyl)phenyl]methylidene}amino)oxy]propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. TTR:ligand complexes were prepared from crystals soaked with a tenfold molar excess of ligand for more than two weeks., VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.78 Å R-free 0.273 |
| 3GLZ Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic acid (inhibitor 11) Deposited 2009-03-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 1BD 3-[({(1E)-[2-(trifluoromethyl)phenyl]methylidene}amino)oxy]propanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. TTR:ligand complexes were prepared from crystals soaked with a tenfold molar excess of ligand for more than two weeks., VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 1.78 Å R-free 0.273 |
| 3GPS Crystal structure of the F87M/L110M mutant of human transthyretin at pH 5.5 Deposited 2009-03-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain C
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain D
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M | ZN ZINC ION × 12 ACT ACETATE ION × 10 GOL GLYCEROL × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.78 Å R-free 0.254 |
| 3GRB Crystal structure of the F87M/L110M mutant of human transthyretin at pH 6.5 Deposited 2009-03-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain C
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain D
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M | ZN ZINC ION × 12 GOL GLYCEROL × 7 ACT ACETATE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 6.5; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.75 Å R-free 0.260 |
| 3GRG Crystal structure of the F87M/L110M mutant of human transthyretin at pH 7.5 Deposited 2009-03-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain C
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain D
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M | ZN ZINC ION × 12 ACT ACETATE ION × 7 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 7.5; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.90 Å R-free 0.255 |
| 3GS0 Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic acid (inhibitor 16) Deposited 2009-03-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 6BD (2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks., VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.85 Å R-free 0.269 |
| 3GS0 Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic acid (inhibitor 16) Deposited 2009-03-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 6BD (2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks., VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.85 Å R-free 0.269 |
| 3GS4 Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor 15) Deposited 2009-03-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 7BD 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks. , VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.78 Å R-free 0.278 |
| 3GS4 Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor 15) Deposited 2009-03-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 7BD 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks. , VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.78 Å R-free 0.278 |
| 3GS7 Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibitor 13) Deposited 2009-03-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 8BD 3-({[(1Z)-(2-methoxyphenyl)methylidene]amino}oxy)propanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks.
, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.80 Å R-free 0.266 |
| 3GS7 Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibitor 13) Deposited 2009-03-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21 to 147
Chain B
21–147（127 aa）
Fragment：UNP residues 21 to 147
|
Not recorded | 8BD 3-({[(1Z)-(2-methoxyphenyl)methylidene]amino}oxy)propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks.
, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 1.80 Å R-free 0.266 |
| 3HJ0 Transthyretin in complex with a covalent small molecule kinetic stabilizer Deposited 2009-05-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 30-147
Chain B
21–147（127 aa）
Fragment：UNP residues 30-147
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | A93 4-fluorophenyl 3-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 1.34 Å R-free 0.182 |
| 3I9A Crystal structure of human transthyretin variant A25T - #1 Deposited 2009-07-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A25T Mutation：A25T | PGE TRIETHYLENE GLYCOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1 uL 5 mg/mL TTR + 1 uL well solution composed by 0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I#14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.65 Å R-free 0.227 |
| 3I9I Crystal structure of human transthyretin variant A25T - #2 Deposited 2009-07-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Mutation：A45T Mutation：A45T | PGE TRIETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；293 K；0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I#14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.237 |
| 3I9I Crystal structure of human transthyretin variant A25T - #2 Deposited 2009-07-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Mutation：A45T Mutation：A45T | PGE TRIETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；293 K；0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I#14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.237 |
| 3I9P Crystal structure of human transthyretin - wild type Deposited 2009-07-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1 uL 5 mg/mL wtTTR + 1 uL well solution - 0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I #14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.255 |
| 3I9P Crystal structure of human transthyretin - wild type Deposited 2009-07-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1 uL 5 mg/mL wtTTR + 1 uL well solution - 0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I #14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.255 |
| 3IMR Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dichlorostyryl)phenol Deposited 2009-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IW1 2,6-dibromo-4-[(E)-2-(2,6-dichlorophenyl)ethenyl]phenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.70 Å R-free 0.217 |
| 3IMS Transthyretin in complex with 2,6-dibromo-4-(2,6-dichlorophenethyl)phenol Deposited 2009-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IW2 2,6-dibromo-4-[2-(2,6-dichlorophenyl)ethyl]phenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.40 Å R-free 0.197 |
| 3IMT Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromophenol Deposited 2009-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IW3 4-[(E)-2-(4-aminophenyl)ethenyl]-2,6-dibromophenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.40 Å R-free 0.190 |
| 3IMU Transthyretin in complex with (E)-4-(3-aminostyryl)-2,6-dibromoaniline Deposited 2009-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IW4 4-[(E)-2-(3-aminophenyl)ethenyl]-2,6-dibromoaniline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.40 Å R-free 0.191 |
| 3IMV Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromoaniline Deposited 2009-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IW5 4-[(E)-2-(4-aminophenyl)ethenyl]-2,6-dibromoaniline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.47 Å R-free 0.201 |
| 3IMW Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dimethoxystyryl)aniline Deposited 2009-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IW6 2,6-dibromo-4-[(E)-2-(2,6-dimethoxyphenyl)ethenyl]aniline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.31 Å R-free 0.196 |
| 3IPB Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (11 carbon linker). Deposited 2009-08-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | JZD 2,2'-{undecane-1,11-diylbis[oxy(3,5-dichlorobenzene-4,1-diyl)imino]}dibenzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；25-
32% v/v PEG550-monomethyl ether, 70 mM NaAc buffer pH 4-5 and 100 mM NaCl, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.229 |
| 3IPE Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (7 carbon linker). Deposited 2009-08-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | JZE 2,2'-{heptane-1,7-diylbis[oxy(3,5-dichlorobenzene-4,1-diyl)imino]}dibenzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.5；298 K；25-
32% v/v PEG550-monomethyl ether, 70 mM NaAc buffer pH 4-5 and 100 mM NaCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.40 Å R-free 0.196 |
| 3KGS V30M mutant human transthyretin (TTR) (apoV30M) pH 7.5 Deposited 2009-10-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 20-147
Chain B
21–147（127 aa）
Fragment：UNP residues 20-147
|
Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.80 Å R-free 0.248 |
| 3KGT V30M mutant human transthyretin (TTR) complexed with genistein (V30M:GEN) pH 7.5 Deposited 2009-10-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Mutation：V30M Mutation：V30M | GEN GENISTEIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.95 Å R-free 0.241 |
| 3KGU Wild type human transthyretin (TTR) complexed with genistein (TTRwt:GEN) pH 7.5 Deposited 2009-10-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | GEN GENISTEIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.85 Å R-free 0.234 |
| 3M1O Human Transthyretin (TTR) complexed with 2-((3,5-dichloro-4-hydroxyphenyl)amino)benzoic acid Deposited 2010-03-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CJZ 2-[(3,5-dichloro-4-hydroxyphenyl)amino]benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；25- 32% V/V PEG550-MONOMETHYL ETHER, 70 MM NAAC BUFFER PH 4-5 AND 100 MM NACL, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.20 Å R-free 0.171 |
| 3NEE Wild type human transthyretin (TTR) complexed with GC-1 (TTRwt:GC-1) Deposited 2010-06-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
Chain B
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
|
Not recorded | B72 {4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid × 4 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.55 Å R-free 0.217 |
| 3NEO Wild type human transthyretin (TTR) complexed with GC-24 (TTRwt:GC-24) Deposited 2010-06-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
Chain B
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
|
Not recorded | G24 [4-(3-BENZYL-4-HYDROXYBENZYL)-3,5-DIMETHYLPHENOXY]ACETIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.00 Å R-free 0.220 |
| 3NES V30M mutant human transthyretin (TTR) complexed with GC-1 (V30M:GC-1) Deposited 2010-06-09 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
Chain B
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
|
Mutation：V30M Mutation：V30M | B72 {4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid × 4 GOL GLYCEROL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.75 Å R-free 0.223 |
| 3NEX V30M mutant human transthyretin (TTR) complexed with GC-24 (V30M:GC-24) Deposited 2010-06-09 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
Chain B
30–145（116 aa）
Fragment：UNP RESIDUES 30-145
|
Mutation：V30M Mutation：V30M | GOL GLYCEROL × 4 G24 [4-(3-BENZYL-4-HYDROXYBENZYL)-3,5-DIMETHYLPHENOXY]ACETIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.70 Å R-free 0.207 |
| 3NG5 Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG) Deposited 2010-06-11 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30M Mutation：V30M | KDH (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate × 6 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.3；293 K；200MM CITRATE, 3M AMMONIUM SULFATE, pH 5.3, EVAPORATION, temperature 293K
|
Resolution 1.70 Å R-free 0.227 |
| 3OZK Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4) Deposited 2010-09-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A25T Mutation：A25T | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes sodium pH 7.5, 28% PEG 400, 0.2 calcium chloride dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 293K, complex obtained by soaking crystal with ligand.
|
Resolution 1.90 Å R-free 0.236 |
| 3OZL Crystal structure of human transthyretin variant A25T in complex with flufenamic acid. Deposited 2010-09-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A25T Mutation：A25T | FLF 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1 M Hepes sodium pH 7.5, 28% PEG 400, 0.2 calcium chloride dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 293K, soaking for 1 h with ligand.
|
Resolution 1.90 Å R-free 0.247 |
| 3P3R Transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone Deposited 2010-10-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 3M1 (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.25 Å R-free 0.180 |
| 3P3S Human transthyretin (TTR) complexed with (Z)-5-(3,5-dibromo-4-hydroxybenzylidene)-imino-1-methylimidazolidin-4-one Deposited 2010-10-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 3M2 (5Z)-2-amino-5-(3,5-dibromo-4-hydroxybenzylidene)-1-methyl-1,5-dihydro-4H-imidazol-4-one × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.60 Å R-free 0.232 |
| 3P3T Human transthyretin (TTR) complexed with 4-(3-(2-flourophenoxy)propyl)-3,5-dimethyl-1H-pyrazole Deposited 2010-10-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 3M3 4-[3-(2-fluorophenoxy)propyl]-3,5-dimethyl-1H-pyrazole × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.45 Å R-free 0.199 |
| 3P3U Human transthyretin (TTR) complexed with 5-(2-ethoxyphenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazole Deposited 2010-10-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 3M4 4-[5-(2-ethoxyphenyl)-1,2,4-oxadiazol-3-yl]pyridine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.50 Å R-free 0.198 |
| 3SSG Structure of transthyretin L55P in complex with Zn Deposited 2011-07-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
|
Mutation：L55P | ZN ZINC ION × 8 CAC CACODYLATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；287 K；3% w/v PEG 8000, 0.1M cacodylate pH 6.5, 5 mM Zn acetate, VAPOR DIFFUSION, HANGING DROP, temperature 287K
|
Resolution 2.00 Å R-free 0.247 |
| 3TCT Structure of wild-type TTR in complex with tafamidis Deposited 2011-08-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：unp residues 21-147
Chain B
21–147（127 aa）
Fragment：unp residues 21-147
|
Not recorded | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298.0K
|
Resolution 1.30 Å R-free 0.192 |
| 3TFB Transthyretin natural mutant A25T Deposited 2011-08-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Mutation：A45T Mutation：A45T | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；100 mM HEPES, 200 mM CaCl2 and 28% PEG400, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.03 Å R-free 0.239 |
| 3U2I X-ray crystal structure of human Transthyretin at room temperature Deposited 2011-10-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–147（116 aa）
Fragment：UNP residues 32-147
Chain B
32–147（116 aa）
Fragment：UNP residues 32-147
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；2.0M tri-ammonium citrate(pD7.4), 0.4M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.239 |
| 3U2J Neutron crystal structure of human Transthyretin Deposited 2011-10-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
32–147（116 aa）
Fragment：UNP residues 32-147
Chain B
32–147（116 aa）
Fragment：UNP residues 32-147
|
Not recorded | No recorded non-water small molecule |
NEUTRON DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；1.85M tri-ammonium citrate, pD7.4, 0.4M MgCl2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.272 |
| 3W3B Crystal structure of wild-type human transthyretin Deposited 2012-12-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.235 |
| 4ABQ CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-1 Deposited 2011-12-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–144（124 aa）
Fragment：RESIDUES 21-144
Chain B
21–144（124 aa）
Fragment：RESIDUES 21-144
|
Not recorded | 4V2 3-(5-MERCAPTO-1,3,4-OXADIAZOL-2-YL)-PHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.70 Å R-free 0.242 |
| 4ABU CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-2 Deposited 2011-12-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–144（124 aa）
Fragment：RESIDUES 21-144
Chain B
21–144（124 aa）
Fragment：RESIDUES 21-144
|
Not recorded | FT1 4-(2,4-dichlorophenoxy)-3-hydroxybenzaldehyde × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.86 Å R-free 0.254 |
| 4ABV CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-3 Deposited 2011-12-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–144（124 aa）
Fragment：RESIDUES 21-144
Chain B
21–144（124 aa）
Fragment：RESIDUES 21-144
|
Not recorded | FT2 5-(chloromethyl)-2-(2,4-dichlorophenoxy)phenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.80 Å R-free 0.246 |
| 4ABW Crystal Structure of Transthyretin in Complex With Ligand C-6 Deposited 2011-12-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–144（124 aa）
Fragment：RESIDUES 21-144
Chain B
21–144（124 aa）
Fragment：RESIDUES 21-144
|
Not recorded | 42M [4-(2,4-dinitrophenoxy)-3-methoxyphenyl]methanol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.70 Å R-free 0.257 |
| 4AC2 CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-7 Deposited 2011-12-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–144（124 aa）
Fragment：RESIDUES 21-144
Chain B
21–144（124 aa）
Fragment：RESIDUES 21-144
|
Not recorded | 43F 2,4-DICHLORO-1-[4-(CHLOROMETHYL)-2-METHOXYPHENOXY]BENZENE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.81 Å R-free 0.236 |
| 4AC4 CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-18 Deposited 2011-12-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | HKA 3-METHOXY-4-PHENOXYBENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.80 Å R-free 0.258 |
| 4ACT CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-17 Deposited 2011-12-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | FT0 3-hydroxy-4-phenoxybenzaldehyde × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.80 Å R-free 0.265 |
| 4ANK Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two T4 binding sites. Deposited 2012-03-20 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
|
Resolution 1.70 Å R-free 0.250 |
| 4D7B Structure of human transthyretin in complex with Tolcapone Deposited 2014-11-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | TCW Tolcapone × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.15 Å R-free 0.201 |
| 4DER Crystal Structure of the Wild Type TTR Binding Apigenin (TTRwt:API) Deposited 2012-01-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Not recorded | AGI 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one × 4 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.235 |
| 4DES Crystal Structure of the Wild Type TTR Binding Chrysin (TTRwt:CHR) Deposited 2012-01-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Not recorded | 57D chrysin × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.75 Å R-free 0.226 |
| 4DET Crystal Structure of the Wild Type TTR Binding Kaempferol (TTRwt:KAE) Deposited 2012-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Not recorded | KMP 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.05 Å R-free 0.223 |
| 4DEU Crystal Structure of the Wild Type TTR Binding Naringenin (TTRwt:NAR) Deposited 2012-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Not recorded | EDO 1,2-ETHANEDIOL × 20 NAR NARINGENIN × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.213 |
| 4DEW Crystal Structure of the Wild Type TTR Binding Luteolin (TTRwt:LUT) Deposited 2012-01-22 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.199 |
| 4FI6 Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide Deposited 2012-06-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 0U7 3-[5-(3,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl fluoride × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
|
Resolution 1.46 Å R-free 0.182 |
| 4FI7 Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide Deposited 2012-06-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 0UA 3-[5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl fluoride × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
|
Resolution 1.40 Å R-free 0.205 |
| 4FI8 Kinetic Stabilization of transthyretin through covalent modification of K15 by 4-bromo-3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide Deposited 2012-06-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 0UC 4-bromo-3-[5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl fluoride × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
|
Resolution 1.22 Å R-free 0.197 |
| 4HIQ The Structure of V122I Mutant Transthyretin in Complex with AG10 Deposited 2012-10-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V122I Mutation：V122I | 16V 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.18 Å R-free 0.186 |
| 4HIS The Structure of V122I Mutant Transthyretin in Complex with Tafamidis Deposited 2012-10-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V122I Mutation：V122I | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.20 Å R-free 0.172 |
| 4HJS Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)ethanesulfonamide Deposited 2012-10-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Not recorded | 18J N-{4-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]phenyl}ethanesulfonamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.22 Å R-free 0.224 |
| 4HJT Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)phenyl)propionamide Deposited 2012-10-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 18A N-{4-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]phenyl}propanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.45 Å R-free 0.187 |
| 4HJU Transthyretin in complex with (E)-N-(3-(4-hydroxy-3,5-dimethylstyryl)phenyl)acrylamide Deposited 2012-10-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 16L N-{3-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]phenyl}prop-2-enamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.35 Å R-free 0.188 |
| 4I85 Crystal structure of transthyretin in complex with CHF5074 at neutral pH Deposited 2012-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：Transthyretin (unp residues 21-147)
Chain B
21–147（127 aa）
Fragment：Transthyretin (unp residues 21-147)
|
Not recorded | H50 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.67 Å R-free 0.230 |
| 4I87 Crystal structure of TTR variant I84S in complex with CHF5074 at acidic pH Deposited 2012-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：Transthyretin (unp residues 21-147)
Chain B
21–147（127 aa）
Fragment：Transthyretin (unp residues 21-147)
|
Mutation：I84S Mutation：I84S | H50 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；15% (w/v) PEG 2000 monomethylether, 0.1 M
ammonium sulfate, 0.05 M sodium acetate buffer, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.69 Å R-free 0.211 |
| 4I89 Crystal structure of transthyretin in complex with diflunisal at acidic pH Deposited 2012-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：Transthyretin (unp residues 21-147)
Chain B
21–147（127 aa）
Fragment：Transthyretin (unp residues 21-147)
|
Mutation：I84S Mutation：I84S | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；15% (w/v) PEG 2000 monomethylether, 0.1 M ammonium sulfate, 0.05 M sodium acetate buffer, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.69 Å R-free 0.222 |
| 4IIZ Crystal structure of wild-type human transthyretin in complex with lumiracoxib Deposited 2012-12-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LUR {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.240 |
| 4IK6 Crystal structure of human transthyretin in complex with lumiracoxib Deposited 2012-12-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LUR {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å R-free 0.238 |
| 4IK7 Crystal structure of human transthyretin in complex with indomethacin Deposited 2012-12-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IMN INDOMETHACIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å R-free 0.244 |
| 4IKI Crystal structure of wild-type human transthyretin in complex with indomethacin Deposited 2012-12-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IMN INDOMETHACIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；291 K；10mg/mL wtTTR, 22% peg 400, 100mM Tris pH 7.4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å R-free 0.235 |
| 4IKJ Crystal structure of wild-type human transthyretin in complex with sulindac Deposited 2012-12-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SUZ [(1Z)-5-fluoro-2-methyl-1-{4-[methylsulfinyl]benzylidene}-1H-inden-3-yl]acetic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；10mg/mL wtTTR, 0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400 (Hampton Research's Crystal Screen I, #14), VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å R-free 0.257 |
| 4IKK Crystal structure of wild-type human transthyretin in complex with sulindac Deposited 2012-12-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SUZ [(1Z)-5-fluoro-2-methyl-1-{4-[methylsulfinyl]benzylidene}-1H-inden-3-yl]acetic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；10mg/mL wtTTR, 0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400
(Hampton Research's Crystal Screen I, #14), VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.90 Å R-free 0.250 |
| 4IKL Crystal structure of wild-type human transthyretin in complex with sulindac Deposited 2012-12-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SUZ [(1Z)-5-fluoro-2-methyl-1-{4-[methylsulfinyl]benzylidene}-1H-inden-3-yl]acetic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；291 K；10mg/mL wtTTR, 22% peg 400, 100mM Tris pH 7.4, 100 mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.90 Å R-free 0.244 |
| 4KY2 Transthyretin in complex with the fluorescent folding sensor (E)-7-hydroxy-3-(4-hydroxy-3,5-dimethylstyryl)-4-methyl-2H-chromen-2-one Deposited 2013-05-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 1W3 7-hydroxy-3-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]-4-methyl-2H-chromen-2-one × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 1.13 Å R-free 0.174 |
| 4L1S Covalent modification of transthyretin K15 by yielding the fluorescent conjugate (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzamide Deposited 2013-06-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 1W4 S-(4-fluorophenyl) 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzenecarbothioate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
|
Resolution 1.50 Å R-free 0.185 |
| 4L1T Transthyretin in complex with (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzoic acid Deposited 2013-06-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 1WZ 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 1.16 Å R-free 0.188 |
| 4MAS High Resolution Structure of Wild Type Human Transthyretin in Complex with 3,3',5,5'-tetrachloro-[1,1'-biphenyl]-4,4'diol Deposited 2013-08-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | PCQ 3,5,3',5'-TETRACHLORO-BIPHENYL-4,4'-DIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；4 mg/ML wt-TTR in 10 mM sodium phosphate, 100 mM potassium chloride, pH 7.6, co-crystallized with inhibitor, crystallization solution: 1.395 M sodium citrate, 3.5% v/v glycerol, pH 5.5, cryoprotectant: 1.395 M sodium citrate, pH 5.5, 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.22 Å R-free 0.173 |
| 4MRB Wild Type Human Transthyretin pH 7.5 Deposited 2013-09-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | CA CALCIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；293 K；100mM HEPES, 200mM CaCl2, 28% PEG400 v/v, pH 7.5, VAPOR DIFFUSION, temperature 293K
|
Resolution 1.27 Å R-free 0.209 |
| 4MRC Human Transthyretin Ser52Pro Mutant Deposited 2013-09-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
22–147（126 aa）
Fragment：UNP residues 22-147
Chain B
22–147（126 aa）
Fragment：UNP residues 22-147
|
Mutation：S52P Mutation：S52P | CA CALCIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；293 K；100mM HEPES, 200mM CaCl2, 28% PEG400 v/v, pH 7.5, VAPOR DIFFUSION, temperature 293K
|
Resolution 1.54 Å R-free 0.228 |
| 4N85 Crystal structure of human transthyretin Deposited 2013-10-17 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | CA CALCIUM ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；34-40% PEG 400, 0.4M CaCl2, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.239 |
| 4N86 Crystal structure of human transthyretin complexed with glabridin Deposited 2013-10-17 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | GBJ 4-[(3R)-8,8-dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diol × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；34.2% PEG 400, 0.36M CaCl2, 0.09M HEPES, 1mM glabridin, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.259 |
| 4N87 Crystal structure of V30M mutant human transthyretin complexed with glabridin Deposited 2013-10-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | GBJ 4-[(3R)-8,8-dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；32% PEG 400, 0.4M CaCl2, 0.1M HEPES, 0.5mM Glabridin, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.79 Å R-free 0.253 |
| 4PM1 Human transthyretin (TTR) complexed with 16-alpha-bromo-estradiol Deposited 2014-05-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | ESZ (14beta,16alpha,17alpha)-16-bromoestra-1,3,5(10)-triene-3,17-diol × 4 EDO 1,2-ETHANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.2；293 K；Protein: 5 mg/ml TTR dialysed against 0.1 M NaCl, 0.05M Na acetate, pH 5.5.
Precipitant:: 70% (30% PEG 4000, 0.2M imidazole malate, pH 6.0) 30% (18% monomethyl PEG 2000, 0.1 M sodium cacodylate, pH 6.5).
Cryoprotectant: 40% (25 % diethylene glycol + 12.5 % MPD + 37.5 % 2,3-butanediol + 12.5 % 1,4-dioxane) 50% (12.5% MPEG 5K, 25% MPEG 550) 0.1 M (mixed Na propionate, Na cacodylate, Bis-Tris-propane 50% at pH 4.0 and 50% pH 9.5)
|
Resolution 1.23 Å R-free 0.211 |
| 4PME Human transthyretin (TTR) complexed with ferulic acid and curcumin. Deposited 2014-05-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–146（118 aa）
Fragment：UNP residues 29-145
Chain B
29–146（118 aa）
Fragment：UNP residues 29-145
|
Not recorded | CUR (1Z,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one × 2 NA SODIUM ION × 2 EDO 1,2-ETHANEDIOL × 2 FER 3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；protein: 5 mg/ml dialysed in 0.1 M NaCl, 0.05 M NaAc, pH 5.5 with 5 milli-M curcumin.
precipitant:: 45% MPEG 2,000, 0.1 M sodium cacodylate, pH 7.5.
Cryoprotectant: 40% mixed (25% dioxane, 25% DMSO, 12.5% ethylene glycol, 12.5% 1,2-propanediol, 12.5% glycerol, 12.5% 2,3-butanediol), 50% (25% MPEG 5000, 0.1 M mixed (Na acetate, ADA, Bicine buffer: 40% pH 4.0 / 60% pH 9.0)
|
Resolution 1.26 Å R-free 0.207 |
| 4PME Human transthyretin (TTR) complexed with ferulic acid and curcumin. Deposited 2014-05-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
29–146（118 aa）
Fragment：UNP residues 29-145
Chain B
29–146（118 aa）
Fragment：UNP residues 29-145
|
Not recorded | CUR (1Z,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one × 1 NA SODIUM ION × 1 EDO 1,2-ETHANEDIOL × 1 FER 3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；protein: 5 mg/ml dialysed in 0.1 M NaCl, 0.05 M NaAc, pH 5.5 with 5 milli-M curcumin.
precipitant:: 45% MPEG 2,000, 0.1 M sodium cacodylate, pH 7.5.
Cryoprotectant: 40% mixed (25% dioxane, 25% DMSO, 12.5% ethylene glycol, 12.5% 1,2-propanediol, 12.5% glycerol, 12.5% 2,3-butanediol), 50% (25% MPEG 5000, 0.1 M mixed (Na acetate, ADA, Bicine buffer: 40% pH 4.0 / 60% pH 9.0)
|
Resolution 1.26 Å R-free 0.207 |
| 4PMF Human transthyretin (TTR) complexed with curcumin Deposited 2014-05-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–145（117 aa）
Fragment：UNP residues 29-146
Chain B
29–145（117 aa）
Fragment：UNP residues 29-146
|
Not recorded | CUR (1Z,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one × 4 NA SODIUM ION × 2 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；Precipitant: 40% MPEG 2,000, 1% dioxane, 0.1 M sodium cacodylate, pH 7.5.
Cryoprotectant: 40% mixed (25% dioxane, 25% DMSO, 12.5% ethylene glycol, 12.5% 1,2-propanediol, 12.5% glycerol, 12.5% 2,3-butanediol) 50% (25% MPEG 5K, 0.1 M mixed (sodium acetate, ADA, bicine 20% pH 4 and 80% pH 9), 3 milli-M Curcumin for 20 min
|
Resolution 1.35 Å R-free 0.209 |
| 4PVL X-ray structure of human transthyretin (TTR) at room temperature to 1.9A resolution Deposited 2014-03-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；2.15M SODIUM MALONATE, 23MG/ML PROTEIN, 100UL DROP, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.85 Å R-free 0.201 |
| 4PVM Neutron structure of human transthyretin (TTR) at room temperature to 2.0A resolution (Laue) Deposited 2014-03-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
Experimental method not declared
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；2.15M SODIUM MALONATE, 23MG/ML PROTEIN, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution not provided |
| 4PVN Neutron structure of human transthyretin (TTR) at room temperature to 2.3A resolution (monochromatic) Deposited 2014-03-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
Experimental method not declared
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；2.15M SODIUM MALONATE, 23MG/ML PROTEIN, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution not provided |
| 4PWE Crystal structure of V30M mutant human transthyretin Deposited 2014-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；30% PEG400, 0.1M HEPES, 0.4M CaCl2, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.40 Å R-free 0.228 |
| 4PWF Crystal structure of V30M mutant human transthyretin complexed with ferulic acid phenethyl ester Deposited 2014-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | PWF 2-phenylethyl (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 4mM ferulic acid phenethyl ester, pH 7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.232 |
| 4PWG Crystal structure of V30M mutant human transthyretin complexed with caffeic acid ethyl ester Deposited 2014-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | 0XR ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 12mM caffeic acid ethyl ester, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.243 |
| 4PWH Crystal structure of V30M mutant human transthyretin complexed with caffeic acid 1,1-dimethylallyl ester Deposited 2014-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | PWH 3-methylbut-2-en-1-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate × 4 CA CALCIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 9mM caffeic acid 1,1-dimethylallyl ester, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.219 |
| 4PWI Crystal structure of V30M mutant human transthyretin complexed with rosmarinic acid Deposited 2014-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | ROA (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 9mM rosmarinic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.49 Å R-free 0.231 |
| 4PWJ Crystal structure of V30M mutant human transthyretin complexed with nordihydroguaiaretic acid Deposited 2014-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | 30Z 4-[(2R,3S)-3-[(3,4-DIHYDROXYPHENYL)METHYL]-2-METHYLBUTYL]BENZENE-1,2-DIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 8mM nordihydroguaiaretic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.55 Å R-free 0.219 |
| 4PWK Crystal structure of V30M mutant human transthyretin complexed with dihydroguaiaretic acid Deposited 2014-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | PWK 4,4'-[(2R,3R)-2,3-dimethylbutane-1,4-diyl]bis(2-methoxyphenol) × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 6mM dihydroguaiaretic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.59 Å R-free 0.231 |
| 4QRF Crystal structure of V30M mutant human transthyretin complexed with caffeic acid phenethyl ester Deposited 2014-06-30 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | QAP 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 1mM caffeic acid phenethyl ester, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.256 |
| 4QXV CRYSTAL STRUCTURE of HUMAN TRANSTHYRETIN IN COMPLEX WITH LUTEOLIN AT 1.1 A RESOLUTION Deposited 2014-07-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 4 GOL GLYCEROL × 6 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；291 K；WT-TTR CONCENTRATION WAS 5 MG/ML IN 10 MM SODIUMPHOSPHATE PH 7.6, 100 MM POTASSIUMCLORIDE. WT-TTR WAS CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH 5 MOLAR EXCESS OF LUTEOLIN IN 3.5% V/V GLYCEROL AND 1.3-1.6 M SODIUM CITRATE AT PH 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K
|
Resolution 1.12 Å R-free 0.152 |
| 4QYA Crystal structure of human transthyretin variant V30M in complex with luteolin Deposited 2014-07-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Mutation：V30M Mutation：V30M | LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；V30M-TTR CONCENTRATION WAS 5 MG/ML IN 10 MM SODIUMPHOSPHATE, PH 7.6, 100 MM POTASSIUMCLORIDE. V30M-TTR WAS CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH 5 MOLAR EXCESS OF LUTEOLIN IN 3.5% V/V GLYCEROL AND 1.3-1.6 M SODIUM CITRATE AT PH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.70 Å R-free 0.198 |
| 4TKW Crystal Structure of Human Transthyretin Leu55Pro Mutant Deposited 2014-05-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：L55P Mutation：L55P | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.80 Å R-free 0.200 |
| 4TL4 Crystal Structure of Human Transthyretin Val30Met Mutant Deposited 2014-05-28 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.75 Å R-free 0.235 |
| 4TL5 Crystal Structure of Human Transthyretin Ser85Pro Mutant Deposited 2014-05-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：S85P Mutation：S85P | NA SODIUM ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.44 Å R-free 0.198 |
| 4TLK Crystal Structure of Human Transthyretin Ser85Pro/Glu92Pro Mutant Deposited 2014-05-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：S85P, E92P Mutation：S85P, E92P | NA SODIUM ION × 4 GOL GLYCEROL × 2 PEG DI(HYDROXYETHYL)ETHER × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.44 Å R-free 0.201 |
| 4TLS Crystal Structure of Human Transthyretin Glu92Pro Mutant Deposited 2014-05-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：E92P Mutation：E92P | PO4 PHOSPHATE ION × 4 GOL GLYCEROL × 2 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.35 Å R-free 0.192 |
| 4TLT Crystal structure of human transthyretin Deposited 2014-05-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.70 Å R-free 0.232 |
| 4TLU Crystal Structure of Human Transthyretin Ala108Trp Mutant Deposited 2014-05-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：A108W Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A108W Non-standard monomer：Yes (specific site not provided by mmCIF) | CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.75 Å R-free 0.213 |
| 4TM9 Crystal Structure of Human Transthyretin Thr119Trp Mutant Deposited 2014-05-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：T119W Mutation：T119W | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.70 Å R-free 0.184 |
| 4TNE Crystal Structure of Human Transthyretin Thr119Tyr Mutant Deposited 2014-06-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：T119Y Mutation：T119Y | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.55 Å R-free 0.201 |
| 4TNF Crystal Structure of Human Transthyretin Lys15Trp Mutant Deposited 2014-06-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：K15W Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：K15W Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.60 Å R-free 0.213 |
| 4TNG Crystal Structure of Human Transthyretin Thr119Met Mutant Deposited 2014-06-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Fragment：UNP residues 29-147
Chain B
29–147（119 aa）
Fragment：UNP residues 29-147
|
Mutation：T119M Mutation：T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.60 Å R-free 0.200 |
| 4TQ8 Dual binding mode for 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid binding to Human transthyretin (TTR) Deposited 2014-06-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 7BD 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid × 4 EDO 1,2-ETHANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；Protein: 5 mg/ml 1 milli-M ligand
Precipitant: 60% (30% PEG-4K, 0.2 M imidazole
malate, pH 6.0) 40% (24% MPEG-5K, 0.1 M sodium acetate, pH 5.5)
Drops: 1 micro-L protein-ligand complex 1 micro-L precipitant.
Cryoprotectant:: 40% (12.5 % diethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 12.5 % DMSO + 12.5 % 1,4-dioxane), 25% MPEG 5K, 0.1 M sodium propionate, sodium cacodylate, Bis-Tris-propane(65% component A pH 4; 35% B pH 9.5 and 1 milli-M ligand.
|
Resolution 1.52 Å R-free 0.210 |
| 4TQH Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)ethanoic acid Deposited 2014-06-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | ES8 [(9H-fluoren-9-ylideneamino)oxy]acetic acid × 4 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；protein: 5 mg/ml 0.05 M NaCl, 0.05 M Na acetate, pH 5.5 with 1 milli-M ligand.
Precipitant: 60% (30% PEG-4K, 0.2 M imidazole malate, pH 6.0) and 40% (24% MPEG-5K, 0.1M sodium acetate, pH 5.5).
Cryoprotectant: 40% (25 % diethylene glycol, 12.5 % MPD, 37.5 % 2,3-butanediol, 12.5 % 1,4-dioxane), 12.5% MPEG 5K, 25% MPEG 550, 100 mM (sodium propionate, sodium cacodylate, Bis-Tris-propane(50% component A pH 4; 50% B pH 9.5) and 1 mM ligand.
|
Resolution 1.51 Å R-free 0.222 |
| 4TQI Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid in a dual binding mode Deposited 2014-06-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 6BD (2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；protein: TTR 10 mg/ml + ligand 0.66 milli-M in 0.1 M NaCl, 0.05 M Na acetate, pH 5.5.
Precipitant: 70% (30% PEG-4K, 0.2 M imidazole malate, pH 6.0) and 30% (12% MPEG-5K, 0.1 M sodium acetate, pH 5.5).
Cryoprotectant: 40% (25 % diethylene glycol, 12.5 % MPD, 37.5 % 2,3-butanediol, 12.5 % 1,4-dioxane), 10% PEG 10K, 0.1 M (mixed sodium propionate, sodium cacodylate, Bis-Tris-propane) (65% component A pH 4; 35% B pH 9.5)
|
Resolution 1.25 Å R-free 0.208 |
| 4TQP Human transthyretin (TTR) complexed with (R)-3-(9H-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide in a dual binding mode Deposited 2014-06-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 48R (2R)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methyl-N-(methylsulfonyl)propanamide × 4 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；Protein: 5 mg/ml in 0.05 M NaCl, 0.05 M sodium acetate, pH 5.5.
Precipitant: 60% (30% PEG-4K, 0.2 M imidazole malate, pH 6.0) and 40% (MPEG-5K, 0.1 M sodium acetate, pH 5.5).
Cryoprotectant: 40% (25 % diethylene glycol, 12.5 % MPD, 37.5 % 2,3-butanediol, 12.5 % 1,4-dioxane), 12.5% MPEG 5K, 25% MPEG 550, 0.1 M (sodium propionate, sodium cacodylate, Bis-Tris-propane: 50% component A pH 4; 50% B pH 9.5) with 1 milli-M ligand.
|
Resolution 1.58 Å R-free 0.198 |
| 4WNJ Crystal structure of Transthyretin-quercetin complex Deposited 2014-10-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | DMS DIMETHYL SULFOXIDE × 4 QUE 3,5,7,3',4'-PENTAHYDROXYFLAVONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；Protein (5 mg/ml) in 20 mM sodium phosphate at pH 7. The reservoir solution was 2.0 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7.0
|
Resolution 1.40 Å R-free 0.193 |
| 4WNS Crystal structure of Transthyretin complexed with pterostilbene Deposited 2014-10-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SO4 SULFATE ION × 4 DMS DIMETHYL SULFOXIDE × 6 3RL Pterostilbene × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；The protein (5 mg/ml) was in 20 mM sodium phosphate at pH 7. Reservoir solution: 2.0 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7.0
|
Resolution 1.40 Å R-free 0.186 |
| 4WO0 Crystal structure of transthyretin in complex with apigenin Deposited 2014-10-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | AGI 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；The protein (5 mg/ml) was in 20 mM sodium phosphate at pH 7. The reservoir solution was 2.0 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7.0.
|
Resolution 1.34 Å R-free 0.206 |
| 4Y9B Crystal structure of V30M mutated transthyretin in complex with alpha-mangostin Deposited 2015-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | MKS 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 CL CHLORIDE ION × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；16% PEG400, 0.1M NaOAc, 0.2 M CaCl2
|
Resolution 1.40 Å R-free 0.235 |
| 4Y9C Crystal structure of V30M mutated transthyretin with bromide in complex with alpha-mangostin Deposited 2015-02-17 | Different ligand/ion Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | MKS 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 BR BROMIDE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.8；293 K；20% PEG400, 0.092 M MES, 0.1 M KBr
|
Resolution 1.49 Å R-free 0.240 |
| 4Y9E Crystal structure of V30M mutated transthyretin in complex with gamma-mangostin Deposited 2015-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | MKT 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 CL CHLORIDE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；16% PEG400, 0.1 M NaOAc, 0.2 M CaCl2
|
Resolution 1.49 Å R-free 0.219 |
| 4Y9G Crystal structure of V30M mutated transthyretin in complex with 3-isomangostin Deposited 2015-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | MKU 5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-3,4-dihydro-2H,6H-pyrano[3,2-b]xanthen-6-one × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；16% PEG400, 0.1 M NaOAc, 0.2 M CaCl2
|
Resolution 1.89 Å R-free 0.258 |
| 4YDM High resolution crystal structure of human transthyretin bound to ligand and conjugates of 3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)phenyl fluorosulfate Deposited 2015-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | 4AJ 2,6-dichloro-4-[5-(3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]phenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol
|
Resolution 1.25 Å R-free 0.172 |
| 4YDN High resolution crystal structure of human transthyretin bound to ligand and conjugates of 4-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)phenyl fluorosulfate Deposited 2015-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | 2WN 4-[5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]phenyl sulfurofluoridate × 4 4B8 2,6-dichloro-4-[5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]phenol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0
|
Resolution 1.35 Å R-free 0.195 |
| 5A6I V122I Transthyretin structure in complex with Tolcalpone Deposited 2015-06-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：RESIDUES 21-147
|
Mutation：YES | TCW Tolcapone × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.86 Å R-free 0.271 |
| 5AKS Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O- glucuronide Deposited 2015-03-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
|
Not recorded | SO4 SULFATE ION × 4 R3X Resveratrol-3-O-glucuronide × 4 DMS DIMETHYL SULFOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
|
Resolution 1.25 Å R-free 0.188 |
| 5AKT Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide Deposited 2015-03-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
|
Not recorded | SO4 SULFATE ION × 4 R4G Resveratrol-4'-O-glucuronide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
|
Resolution 1.35 Å R-free 0.195 |
| 5AKV Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: genistein-7-O- glucuronide Deposited 2015-03-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
|
Not recorded | G7G Genistein-7-O-glucuronide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
|
Resolution 1.52 Å R-free 0.200 |
| 5AL0 Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O-sulfate Deposited 2015-03-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
|
Not recorded | SO4 SULFATE ION × 4 R3S RESVERATROL-3-O-SULFATE × 4 DMS DIMETHYL SULFOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
|
Resolution 1.39 Å R-free 0.209 |
| 5AL8 Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: daidzein-7-O- glucuronide Deposited 2015-03-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：UNP RESIDUES 21-147
|
Not recorded | D75 DAIDZEIN-7-O-GLUCURONIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
|
Resolution 1.50 Å R-free 0.198 |
| 5AYT Crystal structure of transthyretin in complex with L6 Deposited 2015-09-03 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | L6Y 2-oxidanyl-6-(phenylcarbonyl)benzo[de]isoquinoline-1,3-dione × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；18% polyethylene glycol 400, 0.1 M HEPES-NaOH, 0.2 M CaCl2, 1 mM L6
|
Resolution 1.40 Å R-free 0.209 |
| 5BOJ Crystal Structure of Human Transthyretin in Complex with Gemfibrozil Deposited 2015-05-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | 4TX 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；TTRwt was dialyzed against 10 mM sodium phosphate with 100 mM KCl pH 7.6 and concentrated to 5 mg/ml. The resevoir contained 1.3-1.6 M sodium citrate and 3.5% glycerol at pH 5.5. Drop size 3 plus 3 microliter.
|
Resolution 1.75 Å R-free 0.212 |
| 5CLX X-ray structure of perdeuterated TTR mutant - S52P at 1.28A resolution Deposited 2015-07-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：S52P Mutation：S52P | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2.1M di-sodium malonate
|
Resolution 1.28 Å R-free 0.176 |
| 5CLY X-ray structure of TTR mutant - S52P at 1.23A resolution Deposited 2015-07-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：residues 21-147
Chain B
21–147（127 aa）
Fragment：residues 21-147
|
Mutation：S52P Mutation：S52P | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2.5M di-sodium malonate
|
Resolution 1.23 Å R-free 0.186 |
| 5CLZ X-ray structure of TTR mutant - T119M at 1.22A resolution Deposited 2015-07-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Mutation：T119M Mutation：T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；2.1M di-sodium malonate
|
Resolution 1.22 Å R-free 0.197 |
| 5CM1 X-ray structure of perdeuterated TTR mutant - T119M at 1.22A Deposited 2015-07-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Mutation：T119M Mutation：T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；2.4M di-sodium malonate
|
Resolution 1.22 Å R-free 0.196 |
| 5CN3 X-ray structure of wild-type TTR at 1.30A resolution Deposited 2015-07-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；2.15M di-sodium malonate
|
Resolution 1.30 Å R-free 0.180 |
| 5CNH X-ray structure of perdeuterated wild-type TTR at 1.42A resolution Deposited 2015-07-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：UNP residues 21-147
Chain B
21–147（127 aa）
Fragment：UNP residues 21-147
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2.4M di-sodium malonate
|
Resolution 1.42 Å R-free 0.198 |
| 5CR1 Crystal structure of TTR/resveratrol/T4 complex Deposited 2015-07-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 STL RESVERATROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；The protein (5 mg/ml), in 20 mM sodium phosphate, pH 7 was incubated with a reservoir solution containing 2.2 M ammonium sulphate, 0.1 M KCl, 0.03 M sodium phosphate, pH 7.0.
|
Resolution 1.54 Å R-free 0.193 |
| 5DEJ Transthyretin natural mutant A19D Deposited 2015-08-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Mutation：A19D Mutation：A19D | CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100 mM HEPES, 200 mM CaCl2 and 28% PEG400, pH 7.5
|
Resolution 1.37 Å R-free 0.207 |
| 5DEJ Transthyretin natural mutant A19D Deposited 2015-08-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 30-145
Chain B
30–145（116 aa）
Fragment：UNP residues 30-145
|
Mutation：A19D Mutation：A19D | CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100 mM HEPES, 200 mM CaCl2 and 28% PEG400, pH 7.5
|
Resolution 1.37 Å R-free 0.207 |
| 5DWP Crystal Structure of human transthyretin (TTR) processed with the CrystalDirect automated mounting and cryo-cooling technology Deposited 2015-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Fragment：UNP residues 31-145
Chain B
30–145（116 aa）
Fragment：UNP residues 31-145
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M sodium citrate,
1.6 M ammonium sulfate,
pH=5.0
|
Resolution 1.20 Å R-free 0.196 |
| 5E23 Human transthyretin (TTR) complexed with (2,7-Dibromo-fluoren-9-ylideneaminooxy)-acetic acid Deposited 2015-09-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | L32 {[(2,7-dibromo-9H-fluoren-9-ylidene)amino]oxy}acetic acid × 2 DMS DIMETHYL SULFOXIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: 10mg/ml in .1 M NaCl, .050 M Na acetate, pH 5.5.
Complex: 3 micro-L TTR + 3 micro-L 0.02% azide + 1 micro-L inhibitor (.001 M)
Precipitant: 18% PEG4K, 9% PEG10K, 0.12 M imidazole malate pH 6.0, 0.04 M ammonium acetate, pH 4.5.
Cryoprotectant: 10 % diethylene glycol + 5 % MPD + 15 % 2,3-butanediol + 5 % 1,4-dioxane, 12.5% MPEG 5K, 0.1 M mixed ( Na acetate, ADA, Bicine) 60% pH 4 / 40% pH 9)
|
Resolution 1.41 Å R-free 0.197 |
| 5E4A Human transthyretin (TTR) complexed with (2,7-Dichloro-fluoren-9-ylideneaminooxy)-acetic acid. Deposited 2015-10-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
10–146（137 aa）
Chain B
10–146（137 aa）
|
Not recorded | 5JW {[(2,7-dichloro-9H-fluoren-9-ylidene)amino]oxy}acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: TTR at 5 mg/ml + 1.6 milli-M inhibitor.
Precipitant: 18% PEG4K, 0.08M imidazole
malate, pH 6.0 and 13.5% PEG10K, 0.06M ammonium acetate, pH 4.5
Cryoprotectant: 10% diethylene glycol + 5% MPD + 15% 2,3-butanediol + 5% 1,4-dioxane, 25% MPEG 5K, 0.1 M mixed (Na acetate, ADA, Bicine - 60% at pH 4/40% at pH 10)
1 milli-M inhibitor.
|
Resolution 1.33 Å R-free 0.192 |
| 5E4O Human transthyretin (TTR) complexed with (Z)-((3,4-Dichloro-phenyl)-methyleneaminooxy)-acetic acid Deposited 2015-10-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–146（117 aa）
Fragment：UNP residues 30-146
Chain B
30–146（117 aa）
Fragment：UNP residues 30-146
|
Not recorded | L57 ({(Z)-[(3,4-dichlorophenyl)(phenyl)methylidene]amino}oxy)acetic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Protein: 5mg/ml TTR and 1 milli-M inhibitor.
Precipitant: 25% PEG4K, 0.2M imidazole malate, pH 6.0. Slow dessication over 18 months, rehydrated over 4 hours.
Cryoprotectant: 40% CryoSol SM1, 25% MPEG 5K, 0.1M (Na acetate, ADA, Bicine, 80% pH 4.0/20% pH 9.0)
|
Resolution 1.50 Å R-free 0.207 |
| 5EN3 Crystal structure of human transthyretin in complex with luteolin-Cl at 1.25 A resolution Deposited 2015-11-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 7LU 2-[3,4-bis(oxidanyl)phenyl]-7-chloranyl-5-oxidanyl-chromen-4-one × 4 NA SODIUM ION × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；Purified TTR was dialyzed against 10 mM Naphosphate buffer with 100 mM KCl, pH 7.6 and concentrated to 5 mg per ml. Crystallization solution contained 1.3 to 1.6 M sodium citrate and 3.5% glycerol.
|
Resolution 1.25 Å R-free 0.158 |
| 5EZP Human transthyretin (TTR) complexed with 4-hydroxy-chalcone Deposited 2015-11-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
26–147（122 aa）
Chain B
26–147（122 aa）
Chain C
26–147（122 aa）
Chain D
26–147（122 aa）
|
Not recorded | IPJ 4-hydroxy-chalcone × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Protein: 5mg/ML in 0.05 M NaCl, 0.025 M Na acetate, pH 5.5 and 0.001 M 4-hydroxychalcone
Reservoir: 30% PEG4K, 0.1M Tris-HCl, pH 8.5
4 boosts (5 M NaCl)
Cryoprotectant: CryoSol SM1, 25% PEG 4K,
0.1 M (Na acetate, ADA, Bicine) Buffer 20% acid / 80% basic 0.01 M ligand.
|
Resolution 2.50 Å R-free 0.245 |
| 5EZP Human transthyretin (TTR) complexed with 4-hydroxy-chalcone Deposited 2015-11-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
26–147（122 aa）
Chain F
26–147（122 aa）
Chain G
26–147（122 aa）
Chain H
26–147（122 aa）
|
Not recorded | IPJ 4-hydroxy-chalcone × 2 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Protein: 5mg/ML in 0.05 M NaCl, 0.025 M Na acetate, pH 5.5 and 0.001 M 4-hydroxychalcone
Reservoir: 30% PEG4K, 0.1M Tris-HCl, pH 8.5
4 boosts (5 M NaCl)
Cryoprotectant: CryoSol SM1, 25% PEG 4K,
0.1 M (Na acetate, ADA, Bicine) Buffer 20% acid / 80% basic 0.01 M ligand.
|
Resolution 2.50 Å R-free 0.245 |
| 5FO2 Structure of human transthyretin mutant A108I Deposited 2015-11-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：RESIDUES 21-147
|
Mutation：YES Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；0.1M HEPES PH 7.5, 28% PEG400, 0.2M CACL2
|
Resolution 1.45 Å R-free 0.215 |
| 5FW6 Structure of human transthyretin mutant A108V Deposited 2016-02-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：RESIDUES 21-147
|
Mutation：YES Mutation：YES | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.30 Å R-free 0.203 |
| 5FW6 Structure of human transthyretin mutant A108V Deposited 2016-02-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Fragment：RESIDUES 21-147
Chain B
21–147（127 aa）
Fragment：RESIDUES 21-147
|
Mutation：YES Mutation：YES | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.30 Å R-free 0.203 |
| 5FW7 Structure of human transthyretin mutant A109V Deposited 2016-02-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：YES Mutation：YES | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.20 Å R-free 0.185 |
| 5FW8 Structure of human transthyretin mutant E89K Deposited 2016-02-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：YES Mutation：YES | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.204 |
| 5FW8 Structure of human transthyretin mutant E89K Deposited 2016-02-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：YES Mutation：YES | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.204 |
| 5H0V Crystal structure of H88A mutated human transthyretin Deposited 2016-10-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–147（117 aa）
Fragment：UNP residues 31-147
Chain B
31–147（117 aa）
Fragment：UNP residues 31-147
Chain C
31–147（117 aa）
Fragment：UNP residues 31-147
Chain D
31–147（117 aa）
Fragment：UNP residues 31-147
|
Mutation：H88A Mutation：H88A Mutation：H88A Mutation：H88A | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；293 K；16% (+/-)-2-methyl-2,4-pentanediol, 0.2 M MgCl2, 0.1 M sodium acetate
|
Resolution 1.58 Å R-free 0.209 |
| 5H0W Crystal structure of H88F mutated human transthyretin Deposited 2016-10-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–147（117 aa）
Fragment：UNP residues 31-147
|
Mutation：H88F | SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；2.0 M ammonium sulfate, 25% glycerol, 0.1 M MES
|
Resolution 1.90 Å R-free 0.236 |
| 5H0X Crystal structure of H88S mutated human transthyretin Deposited 2016-10-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–147（117 aa）
Fragment：UNP residues 31-147
Chain B
31–147（117 aa）
Fragment：UNP residues 31-147
|
Mutation：H88S Mutation：H88S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.8；293 K；1.8 M ammonium sulfate, 25% glycerol, 0.1 M sodium acetate
|
Resolution 1.57 Å R-free 0.253 |
| 5H0Y Crystal structure of H88Y mutated human transthyretin Deposited 2016-10-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–147（117 aa）
Fragment：UNP residues 31-147
|
Mutation：H88Y | SO4 SULFATE ION × 4 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；2.0 M ammonium sulfate, 25% glycerol, 0.1 M MES
|
Resolution 1.80 Å R-free 0.243 |
| 5H0Z Crystal structure of P113A mutated human transthyretin Deposited 2016-10-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–147（117 aa）
Fragment：UNP residues 31-147
|
Mutation：P113A | SO4 SULFATE ION × 4 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；1.6 M Ammonium sulfate, 0.1 M sodium acetate
|
Resolution 1.74 Å R-free 0.257 |
| 5HJG Crystal Structure of Human Transthyretin in Complex with Tetrabromobisphenol A (TBBPA) Deposited 2016-01-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | XDI 4,4'-propane-2,2-diylbis(2,6-dibromophenol) × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.
|
Resolution 1.40 Å R-free 0.182 |
| 5IHH Crystal structure of human transthyretin in complex with luteolin-MeO at 1.35 A resolution Deposited 2016-02-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 6B5 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-chromen-4-one × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. 7MeOLut was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
|
Resolution 1.35 Å R-free 0.166 |
| 5JID Crystal Structure of Human Transthyretin in Complex with Perfluorooctanoic acid (PFOA) Deposited 2016-04-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 8PF pentadecafluorooctanoic acid × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. PFOA was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.
|
Resolution 1.20 Å R-free 0.163 |
| 5JIM Crystal Structure of Human Transthyretin in Complex with Perfluoroktansulfonsyra (PFOS) Deposited 2016-04-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | P8S heptadecafluoro-1-octanesulfonic acid × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. PFOS was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.
|
Resolution 1.26 Å R-free 0.158 |
| 5JIQ Crystal Structure of Human Transthyretin in Complex with 2,2',4,4'-tetrahydroxybenzophenone (BP2) Deposited 2016-04-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 27M bis(2,4-dihydroxyphenyl)methanone × 4 NA SODIUM ION × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. BP2 was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent
glycerol at pH 5.5. Drop size 3 plus 3 microliter.
|
Resolution 1.45 Å R-free 0.168 |
| 5K1J Human TTR altered by a rhenium tris-carbonyl Pyta-C8 derivative Deposited 2016-05-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 4 EDO 1,2-ETHANEDIOL × 6 ACT ACETATE ION × 6 RE RHENIUM × 4 IMD IMIDAZOLE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5
precipitant: 21% polyethylene glycol 4,000 (PEG4K), 0.14 M imidazole malate, pH 6.0
cryosoak: 40% SM2 (12.5 % ethylene glycol, 12.5 % glycerol, 12.5 %
1,2-propanediol, 25 % DMSO and 37.5% 1,4-dioxane) 50% PEG 8K and 0.2 milli-M of rhenium tris-carbonyl Pyta-C8 derivative.
|
Resolution 1.69 Å R-free 0.222 |
| 5K1N Human TTR altered by a rhenium tris-carbonyl Pyta-C12 derivative Deposited 2016-05-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–147（118 aa）
Chain B
30–147（118 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 4 PEG DI(HYDROXYETHYL)ETHER × 2 RE RHENIUM × 6 ACT ACETATE ION × 2 DMS DIMETHYL SULFOXIDE × 2 IMD IMIDAZOLE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5
precipitant: 21% polyethylene glycol 4,000 (PEG4K), 0.14 M imidazole malate, pH 6.0 + 3.6% polyethylene glycol monomethyl ether (MPEG5K), 30 mM sodium
acetate pH 5.5
cryosoak: 40% SM3 (25 % diethylene glycol + 25 % ethylene glycol + 25 % glycerol + 25 % 1,4-dioxane) 50% PEG 8K and 0.5 milli-M of rhenium tris-carbonyl Pyta-C12 derivative.
|
Resolution 1.81 Å R-free 0.224 |
| 5L4F Crystal Structure of Human Transthyretin in Complex with 2,6-Dinitro-p-cresol (DNPC) Deposited 2016-05-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 6J1 2,6-Dinitro-p-cresol × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. DNPC was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
|
Resolution 1.48 Å R-free 0.194 |
| 5L4I Crystal Structure of Human Transthyretin in Complex with Clonixin Deposited 2016-05-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 6J3 2-(3-chloro-2-methylanilino)pyridine-3-carboxylic acid × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. Clonixin was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
|
Resolution 1.45 Å R-free 0.179 |
| 5L4J Crystal Structure of Human Transthyretin in Complex with 4,4'-Dihydroxydiphenyl sulfone (Bisphenol S, BPS) Deposited 2016-05-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 6JD 4-(4-hydroxyphenyl)sulfonylphenol × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. BPS was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
|
Resolution 1.62 Å R-free 0.216 |
| 5L4M Crystal Structure of Human Transthyretin in Complex with 3,5,6-Trichloro-2-pyridinyloxyacetic acid (Triclopyr) Deposited 2016-05-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | SBK Triclopyr × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodium phosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. Triclopyr was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
|
Resolution 1.58 Å R-free 0.198 |
| 5LLL Crystal structure of DACM wild type Transthyretin Deposited 2016-07-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M CaCl2
0.1 M HEPES sodium pH 7.5
28% v/v PEG 400
|
Resolution 1.42 Å R-free 0.217 |
| 5LLV Crystal structure of DACM F87M/L110M Transthyretin mutant Deposited 2016-07-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | CL CHLORIDE ION × 3 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；293 K；0.2 M CaCl2
0.1 M Sodium Acetate pH 4.6
20% v/v 2-propanol
|
Resolution 1.70 Å R-free 0.223 |
| 5N5Q Human TTR altered conformation from soaking in iron chloride. Deposited 2017-02-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Not recorded | ACT ACETATE ION × 6 FFE [bis(oxidanyl)-[tetrakis(oxidanyl)ferriooxy]ferrio]oxy-pentakis(oxidanyl)iron × 2 FE FE (III) ION × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 27 % polyethylene glycol 4,000, 0.2 M imidazole malate, pH 6.0. cryosoak: 40%
SM3 (, 25 % MPEG 5K, 25 %
diethylene glycol + 25 % ethylene glycol + 25 % glycerol + 25 % 1,4-dioxane) 25 % MPEG 5K,
0.1 M CHC (citric acid, HEPES, CHES: 90 % acid /10 % basic), 30 mM FeCl2, 2 h soak.
|
Resolution 2.53 Å R-free 0.253 |
| 5N62 Human TTR crystals soaked in manganese chloride. Deposited 2017-02-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–146（117 aa）
Chain B
30–146（117 aa）
|
Not recorded | MN MANGANESE (II) ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 26% polyethylene glycol 4,000 (PEG4K), 0.16 M imidazole malate, pH 6.0 cryosoak: 40 % CM7 (12.5 % di-ethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 25 % 1,2-propanediol + 12.5 % DMSO), 25 % MPEG 5K, 5 mM MnCl2, 10 min soak.
|
Resolution 1.80 Å R-free 0.244 |
| 5N7C Human TTR altered conformation from soaking in CuCl2. Deposited 2017-02-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–147（118 aa）
Chain B
30–147（118 aa）
|
Not recorded | CU COPPER (II) ION × 6 PEG DI(HYDROXYETHYL)ETHER × 2 ACT ACETATE ION × 2 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 Precipitant: 21 % PEG4K, .14 M imidazole malate, pH 6.0, 3.6% MPEG 5K, 0.03 M sodium acetate, pH 5.5 cryosoak: 40% CM1 (12.5 % di-ethylene glycol + 12.5 % MPD + 37.5 % 1,2-propanediol + 12.5 % DMSO ), 25 % MPEG 5K,0.1 M CHC (citric acid, HEPES, CHES) 90 % acid at pH 4.0 / 10 % basic at pH 10.0), 30 min soak.
|
Resolution 2.45 Å R-free 0.254 |
| 5NFE Neutron structure of human transthyretin (TTR) T119M mutant at room temperature to 1.85A resolution Deposited 2017-03-14 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
Experimental method not declared
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；1.9M sodium malonate pD5.9, 40mg/ml protein
|
Resolution not provided |
| 5NFW Neutron structure of human transthyretin (TTR) S52P mutant at room temperature to 1.8A resolution (quasi-Laue) Deposited 2017-03-16 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
Experimental method not declared
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.9M sodium malonate pD 6.4, 25mg/ml protein
|
Resolution not provided |
| 5OQ0 Crystal structure of transthyretin mutant 87-110-117 Deposited 2017-08-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
|
Mutation：F87M/L110M/S117E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M sodium phosphate (pH 7.5), 2.2 M ammonium sulphate
|
Resolution 1.94 Å R-free 0.267 |
| 5TTR LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE Deposited 1998-04-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：L55P Mutation：L55P | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.70 Å |
| 5TTR LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE Deposited 1998-04-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
|
Mutation：L55P Mutation：L55P Mutation：L55P Mutation：L55P | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.70 Å |
| 5TTR LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE Deposited 1998-04-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain G
21–147（127 aa）
Chain H
21–147（127 aa）
|
Mutation：L55P Mutation：L55P | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.70 Å |
| 5TZL Structure of transthyretin in complex with the kinetic stabilizer 201 Deposited 2016-11-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IIH 4-(7-chloro-1,3-benzoxazol-2-yl)-2,6-diiodophenol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；WT-TTR at 4 mg/mL and five-fold molar excess compound 201 crystallized from solution containing 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. Crystals cryoprotected by addition of 10% (v/v) glycerol.
|
Resolution 1.40 Å R-free 0.167 |
| 5U48 Wild-type Transthyretin in complex with 5-[(1E)-2-(4-Boronic acid)ethenyl]-1,3-benzenediol Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | S4B {4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl}boronic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% glycerol
|
Resolution 1.50 Å R-free 0.205 |
| 5U49 Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]-1,3-benzenediol Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
|
Not recorded | S2L 5-[(E)-2-(2-chloro-4-hydroxyphenyl)ethenyl]benzene-1,3-diol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 2.22 Å R-free 0.275 |
| 5U4A Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]-1,3-benzenediol Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 7VG {3-chloro-4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl}boronic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 1.90 Å R-free 0.276 |
| 5U4B Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Hydroxyphenyl)ethenyl]benzoic Acid Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | XOS 3-[(E)-2-(4-hydroxyphenyl)ethenyl]benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 1.45 Å R-free 0.207 |
| 5U4C Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Boronic acid)ethenyl]benzoic Acid Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | XBS 3-[(E)-2-(4-boronophenyl)ethenyl]benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 1.70 Å R-free 0.204 |
| 5U4D Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]benzoic Acid Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | XLO 3-[(E)-2-(2-chloro-4-hydroxyphenyl)ethenyl]benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 1.55 Å R-free 0.243 |
| 5U4E Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]benzoic Acid Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | XLB 3-[(E)-2-(4-borono-2-chlorophenyl)ethenyl]benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 1.45 Å R-free 0.198 |
| 5U4F Wild-type Transthyretin in complex with 1,1'-(1E)-(1,2-Ethenediyl)bis[2-chloro-4-boronic acid]benzene Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | IWW [(E)-ethene-1,2-diylbis(3-chloro-4,1-phenylene)]diboronic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 1.50 Å R-free 0.220 |
| 5U4G Wild-type Transthyretin in complex with 2-Boronic Acid-1-[(1E)-2-(3-boronic acid)ethenyl]-4-chlorobenzene Deposited 2016-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 7UV (3-{(E)-2-[2-chloro-4-(hydroxyboranyl)phenyl]ethenyl}phenyl)boronic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
|
Resolution 1.80 Å R-free 0.223 |
| 6D0W Structure of human transthyretin complex with analgesic inhibitor Deposited 2018-04-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | FQ7 2-[(3,5-dichlorophenyl)amino]benzoic acid × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M MES, pH 5.5, PEG 4K, 150 mM AmSO4
|
Resolution 1.70 Å R-free 0.261 |
| 6E6Z Structure of Wild Type Human Transthyretin in Complex with Tafamidis Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Not recorded | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.75 Å R-free 0.223 |
| 6E70 Structure of Wild Type Human Transthyretin in Complex with Diflunisal Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Not recorded | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 CA CALCIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.99 Å R-free 0.229 |
| 6E71 Structure of Human Transthyretin Val30Met/Thr119Met Mutant Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：V30M,T119M Mutation：V30M,T119M | PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；0.2M Lithium Sulfate, 0.1M Tris, 30% (w/v) PEG 4000
|
Resolution 1.50 Å R-free 0.212 |
| 6E72 Structure of Human Transthyretin Val30Met Mutant in Complex with Tafamidis Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：V30M Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：V30M Non-standard monomer：Yes (specific site not provided by mmCIF) | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；0.2M Lithium Sulfate Monohydrate, 20% (w/v) PEG 3350
|
Resolution 1.45 Å R-free 0.205 |
| 6E73 Structure of Human Transthyretin Val30Met Mutant in Complex with Diflunisal Deposited 2018-07-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：V30M Mutation：V30M | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
|
Resolution 1.80 Å R-free 0.220 |
| 6E74 Structure of Human Transthyretin Leu55Pro Mutant in Complex with Tafamidis Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：L55P Mutation：L55P | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.05 M calcium chloride dihydrate, 0.1 M Bis-Tris, 30% PEG monomethyl ether 550
|
Resolution 1.60 Å R-free 0.209 |
| 6E75 Structure of Human Transthyretin Asp38Ala Mutant Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：D38A Mutation：D38A | ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；298 K；30% (v/v) PEG 400, 100 mM Sodium acetate, 200 mM Calcium acetate
|
Resolution 1.50 Å R-free 0.207 |
| 6E76 Structure of Human Transthyretin Asp38Ala/Thr119Met Mutant Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：D38A, T119M Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：D38A, T119M Non-standard monomer：Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 4 SO4 SULFATE ION × 2 ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；298 K；50% (w/v) PEG-400, 0.2M Lithium Sulfate, 0.1M Sodium Acetate
|
Resolution 1.60 Å R-free 0.216 |
| 6E77 Structure of Human Transthyretin Asp38Ala Mutant in Complex with Tafamidis Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：D38A Mutation：D38A | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；2.0M Ammonium sulfate, 0.1M Sodium citrate, 0.2M Potassium sodium tartrate tetrahydrate
|
Resolution 1.60 Å R-free 0.202 |
| 6E78 Structure of Human Transthyretin Asp38Ala Mutant in Complex with Diflunisal Deposited 2018-07-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：D38A Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：D38A Non-standard monomer：Yes (specific site not provided by mmCIF) | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；298 K；30% (W/V) PEG-400, 0.1M Sodium Acetate, 0.2M Calcium Acetate
|
Resolution 1.50 Å R-free 0.213 |
| 6EOY Transthyretin in complex with 4-(1,3-Benzothiazol-2-yl)-2-methylaniline Deposited 2017-10-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Not recorded | BM8 4-(1,3-benzothiazol-2-yl)-2-methyl-aniline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；293 K；acetate buffer 0.2 M pH 4.8-5.4, ammonium sulfate 1.8-2.2 M, 7% glycerol
|
Resolution 1.38 Å R-free 0.195 |
| 6EP1 Transthyretin in complex with 5-(4-nitrophenylazo)-3-iodosalicylic acid Deposited 2017-10-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Fragment：UNP Residues 30-144
Chain B
30–144（115 aa）
Fragment：UNP Residues 30-144
|
Not recorded | BQB 5-(4-nitrophenylazo)-3-iodosalicylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；293 K；acetate buffer 0.2 M pH 4.8-5.4, ammonium sulfate 1.8-2.2 M, 7% glycerol
|
Resolution 1.30 Å R-free 0.190 |
| 6FFT Neutron structure of human transthyretin (TTR) S52P mutant in complex with tafamidis at room temperature to 2A resolution (quasi-Laue) Deposited 2018-01-09 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：P52S Mutation：P52S | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 |
Experimental method not declared
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；2.3M sodium malonate pD 5.9
|
Resolution not provided |
| 6FWD Crystal structure of human transthyretin double mutant R34G/T119M at pH 5.5 Deposited 2018-03-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：R34G, T119M Mutation：R34G, T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；7% glycerol, 1.3 M sodium citrate, pH 5.5
|
Resolution 1.58 Å R-free 0.229 |
| 6FXU Crystal structure of human transthyretin mutant T119M at pH 5.5 Deposited 2018-03-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：T119M Mutation：T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；7% glycerol, 1.3 M sodium citrate, pH 5.5.
|
Resolution 1.36 Å R-free 0.216 |
| 6FZL Crystal structure of human transthyretin double mutant K35T/T119M Deposited 2018-03-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：K35T, T119M Mutation：K35T, T119M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；7% glycerol, 1.3 M sodium citrate, pH 5.5
|
Resolution 1.45 Å R-free 0.192 |
| 6GR7 Crystal Structure Of Human Transthyretin in complex with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) Deposited 2018-06-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | F52 2-[2,4,5-tris(chloranyl)phenoxy]ethanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；The purified human TTR was dialyzed against 10 mM Na-phosphate buffer with 100 mM KCl (pH 7.6) and concentrated to 5 mg/mL The reservoir contained 28% PEG 4K, 0.1M NaAc pH 4.5, 0.2M AmAc. Drop size 3 plus 3 microliter.
|
Resolution 1.40 Å R-free 0.188 |
| 6GRP Crystal Structure Of Human Transthyretin in complex with 3,5,6-trichloro-2-pyridinol (TC2P) Deposited 2018-06-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | F4Z 3,5,6-trichloro-2-pyridinol × 8 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. TC2P was added at 5 x molar excess to the protein. The 1.65 M NaCitrate pH 5.5, 5.8-8.6 % glycerol.
|
Resolution 1.60 Å R-free 0.187 |
| 6IMX Crystal structure of V30M mutated transthyretin in complex with 18-Crown-6 Deposited 2018-10-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；27% PEG400, 0.1 M MES pH 6.5, 0.4 M CaCl2
|
Resolution 1.60 Å R-free 0.224 |
| 6IMY Crystal structure of V30M mutated transthyretin in complex with 4'-caroboxybenzo-18-Crown-6 Deposited 2018-10-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | AJU 2,3,5,6,8,9,11,12,14,15-decahydro-1,4,7,10,13,16-benzohexaoxacyclooctadecine-18-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；27% PEG400, 0.1 M MES pH 6.5, 0.4 M CaCl2
|
Resolution 1.50 Å R-free 0.209 |
| 6KGB Crystal structure of E61K mutated transthyretin Deposited 2019-07-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–146（146 aa）
Chain B
1–146（146 aa）
|
Mutation：E61K Mutation：E61K | CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；27% PEG400, 0.2 M CaCl2, 0.1 M MES-NaOH pH 6.5
|
Resolution 1.30 Å R-free 0.177 |
| 6R66 Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue Deposited 2019-03-26 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | JTN 1-[4-[3,5-bis(chloranyl)phenyl]-3-fluoranyl-phenyl]cyclopropane-1-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
|
Resolution 1.30 Å R-free 0.192 |
| 6R67 Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue Deposited 2019-03-26 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | JTE (2~{R})-2-[4-(3,5-dimethylphenyl)-3-fluoranyl-phenyl]propanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
|
Resolution 1.30 Å R-free 0.205 |
| 6R68 Crystal structure of transthyretin in complex with CHF4795, a flurbiprofen analogue Deposited 2019-03-26 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | JTK (2~{R})-2-[4-[3,5-bis(chloranyl)phenyl]-3-fluoranyl-phenyl]propanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
|
Resolution 1.45 Å R-free 0.198 |
| 6R6I Crystal structure of transthyretin mutant A25T in complex with CHF5074, a flurbiprofen analogue Deposited 2019-03-27 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | H50 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid × 4 PO4 PHOSPHATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
|
Resolution 1.47 Å R-free 0.218 |
| 6SDZ transthyritin derived amyloid fibril from patient with hereditary V30M ATTR amyloidosis Deposited 2019-07-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 11 PDB declaration: undecameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
Chain G
21–147（127 aa）
Chain H
21–147（127 aa）
Chain I
21–147（127 aa）
Chain J
21–147（127 aa）
Chain K
21–147（127 aa）
|
Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；Water extract
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.97 Å |
| 6SUG Crystal structure of transthyretin in complex with 3-deoxytolcapone, a tolcapone analogue Deposited 2019-09-14 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | LVB 3-deoxytolcapone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
|
Resolution 1.21 Å R-free 0.170 |
| 6SUH Crystal structure of human transthyretin in complex with 3-O-methyltolcapone, a tolcapone analogue Deposited 2019-09-14 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | LVE 3-O-methyltolcapone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
|
Resolution 1.26 Å R-free 0.179 |
| 6TI9 Human transthyretin (TTR) complexed with (E)-3-(((3,5-dibromo-2-hydroxybenzylidene)amino)oxy)propanoic acid. Deposited 2019-11-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | ND5 3-[(~{E})-[3,5-bis(bromanyl)-2-oxidanyl-phenyl]methylideneamino]oxypropanoic acid × 4 GOL GLYCEROL × 2 PGO S-1,2-PROPANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5.
|
Resolution 1.45 Å R-free 0.182 |
| 6TJN Human transthyretin (TTR) complexed with (E)-3-(((4-hydroxybenzylidene)amino)oxy)propanoic acid Deposited 2019-11-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | NEK 3-[(~{E})-(4-hydroxyphenyl)methylideneamino]oxypropanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Reservoir: 24% PEG 600, 0.2 Imidazole Malate pH 5.5.
|
Resolution 1.70 Å R-free 0.193 |
| 6TXV A25T Transthyretin structure in complex with Tolcalpone Deposited 2020-01-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Mutation：A25T Mutation：A25T | TCW Tolcapone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.2M CaCl2, 25% PEG400, 0.1M HEPES pH 7.5
|
Resolution 1.60 Å R-free 0.215 |
| 6TXW V30G Transthyretin structure in complex with Tolcalpone Deposited 2020-01-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Not recorded | TCW Tolcapone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.2M CaCl2, 30% PEG400, 0.1M HEPES pH 7.0
|
Resolution 1.15 Å R-free 0.185 |
| 6U0Q Transthyretin in complex with (E)-5,5'-(ethene-1,2-diyl)bis(1,1-dihydroxy-3-oxo-1,3-dihydrobenzo[c][1,2]oxaborol-1-uide) Deposited 2019-08-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | S2B 3-[(~{E})-2-[7,7-bis(oxidanyl)-9-oxidanylidene-8-oxa-7-boranuidabicyclo[4.3.0]nona-1,3,5-trien-3-yl]ethenyl]-7,7-bis(oxidanyl)-8-oxa-7-boranuidabicyclo[4.3.0]nona-1(6),2,4-trien-9-one × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M sodium citrate, 2% v/v glycerol
|
Resolution 1.75 Å R-free 0.222 |
| 6XTK Y114C Transthyretin structure in complex with Tolcalpone Deposited 2020-01-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Mutation：Y114C Mutation：Y114C | TCW Tolcapone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.2M CaCl2, 30% PEG400, 0.1M HEPES, pH 7.0
|
Resolution 1.70 Å R-free 0.220 |
| 7ACU Crystal structure of human transthyretin in complex with Benzbromarone Deposited 2020-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Not recorded | R75 [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.8；293 K；0.2 M acetate buffer pH 4.8, 2.2 M ammonium sulfate, 7% glycerol
|
Resolution 1.54 Å R-free 0.214 |
| 7DT3 Crystal structure of human transthyretin in complex with 4-chloro-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid Deposited 2021-01-04 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | CA CALCIUM ION × 4 HG6 4-chloranyl-9,10-bis(oxidanylidene)anthracene-2-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；PEG400, CaCl2, sodium acetate
|
Resolution 1.20 Å R-free 0.186 |
| 7DT5 Crystal structure of human transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic acid Deposited 2021-01-04 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | CA CALCIUM ION × 4 HH9 4-chloranyl-9-oxidanylidene-xanthene-2-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
|
Resolution 1.25 Å R-free 0.185 |
| 7DT6 Crystal structure of V30M mutated transthyretin in complex with purpurin Deposited 2021-01-04 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | 9TF Purpurin × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaC2l, NaOAc
|
Resolution 1.30 Å R-free 0.211 |
| 7DT8 Crystal structure of V30M mutated transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic acid Deposited 2021-01-04 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | CA CALCIUM ION × 4 HH9 4-chloranyl-9-oxidanylidene-xanthene-2-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
|
Resolution 1.25 Å R-free 0.177 |
| 7EJQ Crystal structure of human transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic acid Deposited 2021-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–146（146 aa）
Chain B
1–146（146 aa）
|
Not recorded | CA CALCIUM ION × 2 J5R 8-chloranyl-9-oxidanylidene-xanthene-3-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG400, CaCl2, NaOAc
|
Resolution 1.15 Å R-free 0.167 |
| 7EJR Crystal structure of V30M mutated transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic acid Deposited 2021-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–146（146 aa）
Chain B
1–146（146 aa）
|
Not recorded | CA CALCIUM ION × 2 J5R 8-chloranyl-9-oxidanylidene-xanthene-3-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
|
Resolution 1.45 Å R-free 0.207 |
| 7ERH Crystal structure of WT-TTR in complex with bithionol Deposited 2021-05-06 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | B1T 2,2'-sulfanediylbis(4,6-dichlorophenol) × 2 CA CALCIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, Tris-HCl pH 8, bithionol
|
Resolution 1.55 Å R-free 0.218 |
| 7ERI Crystal structure of V30M-TTR in complex with triclabendazole Deposited 2021-05-06 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V50M Mutation：V50M | JA9 6-[2,3-bis(chloranyl)phenoxy]-5-chloranyl-2-methylsulfanyl-1H-benzimidazole × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
|
Resolution 1.81 Å R-free 0.222 |
| 7ERJ Crystal structure of V30M-TTR in complex with dichlorophen Deposited 2021-05-06 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V50M Mutation：V50M | JAL 4-chloranyl-2-[(5-chloranyl-2-oxidanyl-phenyl)methyl]phenol × 4 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc, dichlorophen
|
Resolution 1.89 Å R-free 0.211 |
| 7ERK Crystal structure of V30M-TTR in complex with dasatinib Deposited 2021-05-06 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V50M Mutation：V50M | 1N1 N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
|
Resolution 1.70 Å R-free 0.222 |
| 7OB4 Cryo-EM structure of a twisted-dimer transthyretin amyloid fibril from vitreous body of the eye Deposited 2021-04-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 14 PDB declaration: tetradecameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
Chain G
21–147（127 aa）
Chain H
21–147（127 aa）
Chain I
21–147（127 aa）
Chain J
21–147（127 aa）
Chain K
21–147（127 aa）
Chain L
21–147（127 aa）
Chain M
21–147（127 aa）
Chain N
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.22 Å |
| 7Q3I Human Transthyretin expressed in Vibrio natriegens Deposited 2021-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain AAA
21–147（127 aa）
Chain BBB
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；291.15 K；11.6 mg/mL protein in PBS pH 7.4 mixed 1:1 with MgFormate 0.1 M, 24 % PEG1000.
|
Resolution 1.55 Å R-free 0.227 |
| 7Q9L Transthyretin complexed with (E)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diol Deposited 2021-11-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Chain B
29–147（119 aa）
|
Not recorded | 9RJ 4-[(~{E})-2-naphthalen-1-ylethenyl]benzene-1,2-diol × 4 GOL GLYCEROL × 2 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；TTR:SB11 complex at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with
1.3-1.6M sodium citrate and 3.5% glycerol.
|
Resolution 1.45 Å R-free 0.163 |
| 7Q9N Transthyretin complexed with (E)-4-(2-(naphthalen-2-yl)vinyl)benzene-1,2-diol Deposited 2021-11-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Chain B
29–147（119 aa）
|
Not recorded | 9PS 4-[(~{E})-2-naphthalen-2-ylethenyl]benzene-1,2-diol × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；TTR:SB14 complex at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with
1.3-1.6M sodium citrate and 3.5% glycerol.
|
Resolution 1.45 Å R-free 0.171 |
| 7Q9O Complex of Transthyretin with resveratrol exhibits multiple binding modes Deposited 2021-11-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Chain B
29–147（119 aa）
|
Not recorded | STL RESVERATROL × 4 GOL GLYCEROL × 2 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；protein at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with
1.3-1.6M sodium citrate and 3.5% glycerol.
|
Resolution 1.35 Å R-free 0.175 |
| 7QC5 Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound Deposited 2021-11-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | AQI (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；PEG 400, hepes, calcium chloride
|
Resolution 1.20 Å R-free 0.175 |
| 7THA Crystal structure of human transthyretin variant C10A/M13V Deposited 2022-01-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：C10A, M13V Mutation：C10A, M13V | CA CALCIUM ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；Crystals of TTR C10A/M13V were grown at 23 degrees C using sitting-drop vapor diffusion by mixing 0.2 microliters of 5 mg/mL protein in 50 mM Tris pH 7.8 and 0.2 microliters of a crystallization buffer consisting of 0.19M CaCl2, 5% (v/v) glycerol, 0.095M HEPES pH 7.5, and 26.6% (v/v) PEG 400. Crystals were frozen directly without additional cryo-protection by plunging in liquid nitrogen
|
Resolution 1.75 Å R-free 0.211 |
| 7W9Q Crystal structure of V30M-TTR in complex with naringenin derivative-14 Deposited 2021-12-10 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | 90Q (2~{R})-2-(3-chloranyl-4-oxidanyl-phenyl)-5,7-bis(oxidanyl)-2,3-dihydrochromen-4-one × 4 CA CALCIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, NaOAc, CaCl2
|
Resolution 1.60 Å R-free 0.201 |
| 7W9R Crystal structure of V30M-TTR in complex with naringenin derivative-18 Deposited 2021-12-10 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | 91C (2~{R})-2-[3,5-bis(chloranyl)-4-oxidanyl-phenyl]-5,7-bis(oxidanyl)-2,3-dihydrochromen-4-one × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, NaOAc, CaCl2
|
Resolution 2.00 Å R-free 0.225 |
| 7WL6 Crystal structure of I73L mutated human transthyretin Deposited 2022-01-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：I73L Mutation：I73L | MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；293 K；24% PEG400, 0.2 M magnesium acetate, 5% glycerol, 0.1 M Tris-HCl
|
Resolution 1.42 Å R-free 0.210 |
| 7Y1I Crystal Structure of TTR-G67R Deposited 2022-06-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain E
1–147（147 aa）
Chain F
1–147（147 aa）
Chain I
1–147（147 aa）
Chain J
1–147（147 aa）
Chain K
1–147（147 aa）
Chain L
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；AMMONIUM SULFATE, PEG3350
|
Resolution 2.79 Å R-free 0.314 |
| 7Y1I Crystal Structure of TTR-G67R Deposited 2022-06-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain G
1–147（147 aa）
Chain H
1–147（147 aa）
Chain M
1–147（147 aa）
Chain N
1–147（147 aa）
Chain O
1–147（147 aa）
Chain P
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；AMMONIUM SULFATE, PEG3350
|
Resolution 2.79 Å R-free 0.314 |
| 7Y1I Crystal Structure of TTR-G67R Deposited 2022-06-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain Q
1–147（147 aa）
Chain R
1–147（147 aa）
Chain S
1–147（147 aa）
Chain T
1–147（147 aa）
Chain U
1–147（147 aa）
Chain V
1–147（147 aa）
Chain W
1–147（147 aa）
Chain X
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；AMMONIUM SULFATE, PEG3350
|
Resolution 2.79 Å R-free 0.314 |
| 7Y6J Crystal structure of human transthyretin variant A97S at pH 5.4 Deposited 2022-06-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A97S Mutation：A97S | GOL GLYCEROL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.4；277 K；1.75 M Ammonium sulfate, 0.01 M Citrate buffer, pH 5.4
|
Resolution 1.38 Å R-free 0.191 |
| 7YBR Crystal structure of human transthyretin variant A97S complexed with Tolcapone Deposited 2022-06-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A97S Mutation：A97S | TCW Tolcapone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；20% PEG 400, 200 mM Calcium Chloride, 100 mM HEPES
|
Resolution 1.71 Å R-free 0.219 |
| 7YCQ Crystal structure of human transthyretin variant A97S complexed with Diflunisal Deposited 2022-07-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A97S Mutation：A97S | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；1.5 M Ammonium Sulfate, 0.01M citrate buffer; soaked with 800 micromolar Dilfunisal
|
Resolution 1.99 Å R-free 0.222 |
| 7Z60 Human transthyretin (TTR) complexed with Quercetin 3-O-beta-D-galactoside Deposited 2022-03-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 J6O 2-[3,4-bis(oxidanyl)phenyl]-3-[(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5,7-bis(oxidanyl)chromen-4-one × 2 IMD IMIDAZOLE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Protein: 5 mg/ml TTR dialysed against 0.1 M NaCl, 0.05M Na acetate, pH 5.5. Precipitant:80% (30% PEG 4000, 0.2 M Imidazole Malate pH 6.0), 15% ((12% MPEG 5000, 0.1 Sodium Acetate pH 5.5)
|
Resolution 1.40 Å R-free 0.220 |
| 8ADE Wild type ATTR amyloid fibril from senile systemic amyloidosis Deposited 2022-07-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 7 PDB declaration: heptameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
Chain G
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.78 Å |
| 8AWI Crystal structure of Human Transthyretin at 1.15 Angstrom resolution Deposited 2022-08-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
29–147（119 aa）
Chain B
29–147（119 aa）
|
Not recorded | NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；protein at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with 1.3-1.6M sodium citrate and 3.5% glycerol
|
Resolution 1.15 Å R-free 0.166 |
| 8AWW Transthyretin conjugated with a tafamidis derivative Deposited 2022-08-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–145（116 aa）
Chain B
30–145（116 aa）
|
Not recorded | OIT ~{N}-(6-azanylhexyl)-2-[3,5-bis(chloranyl)phenyl]-1,3-benzoxazole-6-carboxamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；1.4 M sodium citrate
|
Resolution 1.60 Å R-free 0.203 |
| 8C85 Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 1 Deposited 2023-01-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | U1F (3,5-dimethylphenyl)(4-hydroxy-3-methoxy-5-nitrophenyl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.2 M calcium acetate hydrate, 0.1 M Tris 7.5, and 25% w/v PEG 2000 MME
|
Resolution 1.19 Å R-free 0.168 |
| 8C86 Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 2 Deposited 2023-01-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | TQ0 (2,4-dimethylphenyl)(4-hydroxy-3-methoxy-5-nitrophenyl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.2 M calcium acetate hydrate, 0.1 M Tris 7.5, and 25% w/v PEG 2000 MME
|
Resolution 1.10 Å R-free 0.158 |
| 8DW5 Complex of Human Transthyretin with 3',5'-Dichlorophenylanthranilic Acid Deposited 2022-07-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
|
Not recorded | FQ7 2-[(3,5-dichlorophenyl)amino]benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.71；298 K；1.3 M sodium citrate pH 5.71, 3% glycerol
|
Resolution 1.52 Å R-free 0.235 |
| 8E7D Cryo-EM structure of wild-type transthyretin amyloid from heart tissue Deposited 2022-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.31 Å |
| 8E7E Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient Deposited 2022-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.61 Å |
| 8E7H Cryo-EM structure of cardiac amyloid fibril from a wild-type amyloidosis patient Deposited 2022-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å |
| 8E7I Cryo-EM structure of cardiac amyloid fibril from a variant ATTR P24S amyloidosis patient Deposited 2022-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Mutation：P24S Mutation：P24S Mutation：P24S Mutation：P24S Mutation：P24S | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.65 Å |
| 8E7J Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient Deposited 2022-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å |
| 8G9R Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient Deposited 2023-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；H2O, 5 mM EDTA
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.28 Å |
| 8GBR Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient Deposited 2023-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；fibrils are in water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 8HEJ Crystal structure of Transthyretin in complex with a covalent inhibitor trans-styrylpyrazole Deposited 2022-11-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–144（114 aa）
Chain B
31–144（114 aa）
|
Not recorded | XHF 2,6-dibromo-4-[(E)-2-(3,5-dimethyl-1H-pyrazol-4-yl)ethenyl]phenol × 4 XHB 2,4,6-trifluorobenzaldehyde × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；Sodium Citrate pH5.5,
Glycerol
|
Resolution 1.54 Å R-free 0.223 |
| 8HY4 Crystal structure of human transthyretin variant A97S at pH 7.6 Deposited 2023-01-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A97S Mutation：A97S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；278 K；0.1 M HEPES, pH 7.6, 38% PEG 400, and 0.4 M CaCl2
|
Resolution 1.53 Å R-free 0.257 |
| 8I00 Crystal structure of A97S transthyretin Deposited 2023-01-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A97S Mutation：A97S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；1.6 M Sodium citrate tribasic dihydrate
|
Resolution 1.80 Å R-free 0.209 |
| 8I0O Crystal structure of Transthyretin variant A97S in monomeric form Deposited 2023-01-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：F87M, L110M, A97S Mutation：F87M, L110M, A97S Mutation：F87M, L110M, A97S Mutation：F87M, L110M, A97S | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1 M Sodium HEPES; MOPS (acid),
0.3M Sodium fluoride; 0.3M Sodium bromide; 0.3M Sodium iodide,
25% v/v MPD; 25% PEG 1000; 25% w/v PEG 3350
|
Resolution 1.88 Å R-free 0.234 |
| 8IG1 Crystal structure of wild-type transthyretin in complex with rafoxanide Deposited 2023-02-20 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | OX9 ~{N}-[3-chloranyl-4-(4-chloranylphenoxy)phenyl]-3,5-bis(iodanyl)-2-oxidanyl-benzamide × 4 NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, sodium acetate pH 4.6
|
Resolution 1.45 Å R-free 0.193 |
| 8II1 Crystal structure of V30M-TTR in complex with BID Deposited 2023-02-24 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | PJO Benziodarone × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
|
Resolution 1.91 Å R-free 0.231 |
| 8II2 Crystal structure of V30M-TTR in complex with BBM Deposited 2023-02-24 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | R75 [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone × 2 CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
|
Resolution 1.80 Å R-free 0.236 |
| 8II3 Crystal structure of V30M-TTR in complex with 6-hydroxy BID Deposited 2023-02-24 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | PKK [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
|
Resolution 1.40 Å R-free 0.212 |
| 8II4 Crystal structure of V30M-TTR in complex with 6-hydroxy BBM Deposited 2023-02-24 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | PKQ [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
|
Resolution 1.50 Å R-free 0.199 |
| 8JNU Crystal structure of V30G mutated human transthyretin Deposited 2023-06-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30G Mutation：V30G | MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.8；293 K；PEG400, MgCl2, glycerol
|
Resolution 1.64 Å R-free 0.207 |
| 8JOK Crystal structure of V30L mutated human transthyretin Deposited 2023-06-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30L Mutation：V30L | MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.9；293 K；PEG400, MgCl2, glycerol
|
Resolution 1.64 Å R-free 0.215 |
| 8JQW Crystal structure of V30I mutated human transthyretin Deposited 2023-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30I Mutation：V30I | MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；PEG400, MgCl2, glycerol
|
Resolution 1.80 Å R-free 0.222 |
| 8PKE ATTRV20I amyloid fibril from hereditary ATTR amloidosis Deposited 2023-06-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
|
Mutation：V20I Mutation：V20I Mutation：V20I Mutation：V20I Mutation：V20I Mutation：V20I | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；Water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.39 Å |
| 8PKF ATTRG47E amyloid fibril from hereditary ATTR amloidosis Deposited 2023-06-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
|
Mutation：G47E Mutation：G47E Mutation：G47E Mutation：G47E Mutation：G47E Mutation：G47E | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；Water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.37 Å |
| 8PKG ATTRV122I amyloid fibril from hereditary ATTR amloidosis Deposited 2023-06-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
|
Mutation：V122I Mutation：V122I Mutation：V122I Mutation：V122I Mutation：V122I Mutation：V122I | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；Water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.99 Å |
| 8PM8 V30M Transthyretin structure in complex with Tolcalpone Deposited 2023-06-28 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30M Mutation：V30M | TCW Tolcapone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291.15 K；0.1M HEPES pH 7.5, 0.2M CaCl2, 25% PEG 400
|
Resolution 1.57 Å R-free 0.231 |
| 8PM9 Crystal structure of human wild type transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) Deposited 2023-06-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | ZP2 (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291.15 K；0.1M HEPES pH8, 0.2M CaCl2, 25% PEG 400
|
Resolution 1.85 Å R-free 0.219 |
| 8PMA Crystal structure of human V30M transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) Deposited 2023-06-28 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V30M Mutation：V30M | ZP2 (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；0.1M HEPES pH7.0, 0.2M CaCl2, 20% PEG 400
|
Resolution 1.20 Å R-free 0.201 |
| 8PMO Crystal structure of human V122I transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) Deposited 2023-06-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：V122I Mutation：V122I | ZP2 (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291.15 K；0.1M HEPES pH 8.0, 0.2M CaCl2, 30% PEG 400
|
Resolution 1.24 Å R-free 0.212 |
| 8TDN Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, wild-type morphology Deposited 2023-07-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；water containing 5-10 mM EDTA
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å |
| 8TDO Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, variant-type morphology Deposited 2023-07-04 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；water containing 5-10 mM EDTA
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å |
| 8U52 Co-crystal structure of human transthyretin conjugated to the stilbene substructure derived from reaction with the fluorogenic covalent kinetic stabilizer A2 Deposited 2023-09-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 1W4 S-(4-fluorophenyl) 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzenecarbothioate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM sodium phosphate, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method.
|
Resolution 1.50 Å R-free 0.194 |
| 8VE0 Human transthyretin covalently modified with A2-derived stilbene in the compressed conformation Deposited 2023-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | 1WZ 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoic acid × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.6
cryo-EM vitrification conditions
Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 6 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
|
Resolution 3.10 Å |
| 8VE1 Human transthyretin covalently modified with A2-derived stilbene in the canonical conformation Deposited 2023-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | 1WZ 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoic acid × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.6
cryo-EM vitrification conditions
Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 6 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
|
Resolution 2.70 Å |
| 8VE2 Unliganded human transthyretin in the canonical conformation Deposited 2023-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.6
cryo-EM vitrification conditions
Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 4 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
|
Resolution 3.30 Å |
| 8VE3 Unliganded human transthyretin in the compressed conformation Deposited 2023-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.6
cryo-EM vitrification conditions
Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 4 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
|
Resolution 3.30 Å |
| 8VE4 Unliganded human transthyretin in the frayed conformation Deposited 2023-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.6
cryo-EM vitrification conditions
Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 4 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
|
Resolution 3.30 Å |
| 8VE5 (Biarylamine-FT2-WT)1(C10A)3-human transthyretin in the compressed conformation Deposited 2023-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | P2C 2-[(3,5-DICHLORO-4-TRIOXIDANYLPHENYL)AMINO]BENZOIC ACID × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.6
cryo-EM vitrification conditions
Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 3 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
|
Resolution 3.40 Å |
| 8VE6 (Biarylamine-FT2-WT)1(C10A)3-human transthyretin in the frayed conformation Deposited 2023-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | P2C 2-[(3,5-DICHLORO-4-TRIOXIDANYLPHENYL)AMINO]BENZOIC ACID × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.6
cryo-EM vitrification conditions
Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 3 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
|
Resolution 4.10 Å |
| 8W1N Structure of transthyretin pathogenic mutation A120S Deposited 2024-02-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：A120S Mutation：A120S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；0.1 M MES at pH 6.0, 10% (v/v) glycerol, 5% (w/v) PEG 1000, and 30% (v/v) PEG 600
|
Resolution 1.60 Å R-free 0.284 |
| 8W2W Structure of transthyretin synthetic mutation A120L Deposited 2024-02-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
|
Mutation：A120L | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1 M sodium cacodylate (pH 6.5), 1M sodium chloride, 10% (v/v) glycerol, and 30% (v/v) PEG 600
|
Resolution 2.07 Å R-free 0.235 |
| 8W42 X-ray crystal structure of V30M-TTR in complex with resveratrol Deposited 2023-08-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | STL RESVERATROL × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
|
Resolution 1.45 Å R-free 0.180 |
| 8W43 X-ray crystal structure of V30M-TTR in complex with piceatannol Deposited 2023-08-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | PIT PICEATANNOL × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
|
Resolution 1.30 Å R-free 0.181 |
| 8W44 X-ray crystal structure of V30M-TTR in complex with oxyresveratrol Deposited 2023-08-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | EZE trans-oxyresveratrol × 6 NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
|
Resolution 1.40 Å R-free 0.181 |
| 8W45 X-ray crystal structure of V30M-TTR in complex with pinostilbene Deposited 2023-08-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | 8KZ 3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-methoxy-phenol × 4 NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
|
Resolution 1.10 Å R-free 0.165 |
| 8W46 X-ray crystal structure of V30M-TTR in complex with pterostilbene Deposited 2023-08-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | 3RL Pterostilbene × 6 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
|
Resolution 1.35 Å R-free 0.188 |
| 8W47 X-ray crystal structure of V30M-TTR in complex with isorhapontigenin Deposited 2023-08-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | P5O 5-[(~{E})-2-(3-methoxy-4-oxidanyl-phenyl)ethenyl]benzene-1,3-diol × 4 NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
|
Resolution 1.40 Å R-free 0.171 |
| 8W48 Neutron and X-ray joint structure of WT-TTR in complex with piceatannol Deposited 2023-08-23 | Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Not recorded | PIT PICEATANNOL × 4 |
Experimental method not declared
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
|
Resolution not provided |
| 8WGS Crystal structure of V30M-TTR in complex with compound 4 Deposited 2023-09-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | WGH [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-(2-ethyl-4-iodanyl-1-benzofuran-3-yl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, sodium acetate, calcium chloride
|
Resolution 1.80 Å R-free 0.214 |
| 8WGT Crystal structure of V30M-TTR in complex with compound 7 Deposited 2023-09-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | WGJ [4,7-bis(chloranyl)-2-ethyl-1-benzofuran-3-yl]-[3,5-bis(iodanyl)-4-oxidanyl-phenyl]methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, sodium acetate, calcium chloride
|
Resolution 1.70 Å R-free 0.231 |
| 8WGU Crystal structure of V30M-TTR in complex with compound 20 Deposited 2023-09-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | WH0 [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-[2-ethyl-4,7-bis(fluoranyl)-1-benzofuran-3-yl]methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, sodium acetate, calcium chloride
|
Resolution 1.51 Å R-free 0.213 |
| 8YQD Crystal structure of human transthyretin variant A97S in complex with Tafamidis Deposited 2024-03-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–144（124 aa）
Chain B
21–144（124 aa）
|
Mutation：A97S Mutation：A97S | 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.2；310 K；0.05 M Calcium chloride dihydrate +0.1 M Bis-Tris +25% PEG 550
|
Resolution 1.69 Å R-free 0.225 |
| 8Z9V Amyloid beta and TTR Deposited 2024-04-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
21–147（127 aa）
Chain b
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.82
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 7.84 Å |
| 9BDM Cryo-EM structure of cardiac amyloid fibril from a variant ATTRV122delta, single filament morphology Deposited 2024-04-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；ice-chilled water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.63 Å |
| 9BDR Cryo-EM structure of cardiac amyloid fibril from a variant ATTRV122delta, double filament morphology 1 Deposited 2024-04-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 10 PDB declaration: decameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
Chain G
21–147（127 aa）
Chain H
21–147（127 aa）
Chain I
21–147（127 aa）
Chain J
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；Fibrils were purified in ice-chilled water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.82 Å |
| 9BYN Cryo-EM structure of amyloid fibril extracted from nerve of a variant ATTR V30M amyloidosis patient Deposited 2024-05-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；Milli-Q water
cryo-EM vitrification conditions
Cryogen ETHANE；Blot-force 0, blotting time 3 sec
|
Resolution 3.36 Å |
| 9BZS Cryo-EM structure of cardiac amyloid fibril from a variant ATTR V30M amyloidosis patient Deposited 2024-05-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；Milli-Q water
cryo-EM vitrification conditions
Cryogen ETHANE；Blot-force 0, blotting time 3 sec
|
Resolution 3.14 Å |
| 9D21 Cryo-EM structure of amyloid fibril extracted from heart of a variant ATTR T60A amyloidosis patient 1 Deposited 2024-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 9D23 Cryo-EM structure of amyloid fibril extracted from heart of a variant ATTR T60A amyloidosis patient 2 Deposited 2024-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.18 Å |
| 9D24 Cryo-EM structure of amyloid fibril extracted from thyroid of a variant ATTR T60A amyloidosis patient 3 Deposited 2024-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.98 Å |
| 9D27 Cryo-EM structure of amyloid fibril extracted from kidney of a variant ATTR T60A amyloidosis patient 3 Deposited 2024-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.19 Å |
| 9D2G Cryo-EM structure of amyloid fibril extracted from liver of a variant ATTR T60A amyloidosis patient 3 Deposited 2024-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å |
| 9FF6 Human transthyretin (TTR) in complex with (E)-4-((((2-methoxybenzyl)oxy)imino)methyl)benzoic acid (Lic157) Deposited 2024-05-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–145（125 aa）
Chain B
21–145（125 aa）
|
Not recorded | A1ICE 4-[(~{Z})-(2-methoxyphenyl)methoxyiminomethyl]benzoic acid × 2 GOL GLYCEROL × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5
|
Resolution 1.40 Å R-free 0.203 |
| 9FF8 Human transthyretin (TTR) in complex with (E)-2-((((2-chlorobenzyl)oxy)imino)methyl)benzoic acid (Lic166) Deposited 2024-05-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 A1ICF 2-[(2-chlorophenyl)methoxyiminomethyl]benzoic acid × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5.
|
Resolution 1.42 Å R-free 0.214 |
| 9FHA Human transthyretin (TTR) in complex with (E)-2-((((2-(trifluoromethyl)benzyl)oxy)imino)methyl)benzoic acid Deposited 2024-05-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | A1IC9 2-[(~{E})-[2-(trifluoromethyl)phenyl]methoxyiminomethyl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5
|
Resolution 1.70 Å R-free 0.234 |
| 9H5X Crystal structure of human V122I transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound Deposited 2024-10-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–145（125 aa）
Chain B
21–145（125 aa）
|
Not recorded | AQI (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；0.1M HEPES pH 7.0, 0.2M CaCl2, 25% PEG 400
|
Resolution 1.70 Å R-free 0.222 |
| 9H5Y Crystal structure of human V30M transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound Deposited 2024-10-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–145（125 aa）
Chain B
21–145（125 aa）
|
Not recorded | AQI (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；0.1M HEPES pH 7.0, 0.2M CaCl2, 25% PEG 400
|
Resolution 1.67 Å R-free 0.220 |
| 9H7A Human Transthyretin in Complex with 3,5-Dichlorobenzenesulfonamide Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | 6OT 3,5-dichlorobenzene-1-sulfonamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.76 Å R-free 0.226 |
| 9H7B Human Transthyretin in Complex with Biphenyl-4-carboxylic Acid Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 2 Z7Z biphenyl-4-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.51 Å R-free 0.228 |
| 9H7C Human Transthyretin in Complex with 4-(1H-imidazol-1-yl)phenol Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 4 MSR 4-(1H-IMIDAZOL-1-YL)PHENOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.27 Å R-free 0.209 |
| 9H7D Human Transthyretin in Complex with 2-(phenylamino)benzoic acid Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 4 EHO 2-phenylazanylbenzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.23 Å R-free 0.188 |
| 9H7E Human Transthyretin in Complex with 4-pyridin-3-ylbenzoic acid Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 2 PQM 4-(pyridin-3-yl)benzoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.43 Å R-free 0.291 |
| 9H7F Human Transthyretin in Complex with 3,5-dichloroaniline Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | A1ISU 3,5-bis(chloranyl)aniline × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.24 Å R-free 0.178 |
| 9H7G Human Transthyretin in Complex with 1H-indole-3-carbonitrile Deposited 2024-10-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 2 98Z 1~{H}-indole-3-carbonitrile × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.49 Å R-free 0.210 |
| 9H7H Human Transthyretin in Complex with Isoquinolin-3-amine Deposited 2024-10-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 2 WLX isoquinolin-3-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.47 Å R-free 0.215 |
| 9H7I Human Transthyretin in Complex with 4-(1H-pyrazol-4-yl)quinoline Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 2 A1ISS 4-(1H-pyrazol-4-yl)quinoline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.21 Å R-free 0.183 |
| 9H7J Human Transthyretin in Complex with 5-methyl-4-phenyl-1H-pyrazol-3-amine Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 4 A1ISY 5-methyl-4-phenyl-1H-pyrazol-3-amine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.30 Å R-free 0.260 |
| 9H7K Human Transthyretin in Complex with 8-(3,5-dimethyl-1H-pyrazol-4-yl)quinoline Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 6 A1IS2 8-(3,5-dimethyl-1H-pyrazol-4-yl)quinoline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.60 Å R-free 0.236 |
| 9H7L Human Transthyretin in Complex with 4-phenyl-1H-pyrazolo[3,4-b]pyridin-3-amine Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 4 A1IS0 4-phenyl-2H-pyrazolo[3,4-b]pyridin-3-amine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.18 Å R-free 0.192 |
| 9H7M Human Transthyretin in Complex with 4-(quinolin-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 4 A1ISV 4-quinolin-8-yl-1H-pyrazolo[3,4-d]pyrimidin-6-amine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.27 Å R-free 0.191 |
| 9H7N Human Transthyretin in Complex with 4-(5-methyl-1H-1,2,4-triazol-3-yl)quinoline Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 2 A1IST 4-(5-methyl-4H-1,2,4-triazol-3-yl)quinoline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.26 Å R-free 0.205 |
| 9H7O Human Transthyretin in Complex with 5-(quinolin-8-yl)pyrimidin-2-amine Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 2 A1ISZ 5-quinolin-8-ylpyrimidin-2-amine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.24 Å R-free 0.193 |
| 9H7P Human Transthyretin S52P Mutant in Complex with 4-(1H-pyrazol-4-yl)quinoline Deposited 2024-10-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Not recorded | CA CALCIUM ION × 4 A1ISS 4-(1H-pyrazol-4-yl)quinoline × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
|
Resolution 1.36 Å R-free 0.205 |
| 9HX3 Amyloid fibril of TTR Deposited 2025-01-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å |
| 9HYW Cryo-EM structure of ATTRv-F64S amyloid fibril from patient skin tissue. Deposited 2025-01-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
Chain F
1–147（147 aa）
Chain G
1–147（147 aa）
Chain H
1–147（147 aa）
Chain I
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 9JIQ Crystal structure of V30M-TTR in complex with bromoxynil Deposited 2024-09-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | A1L36 bromoxynil × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1 M NaOAc pH 4.6
|
Resolution 1.78 Å R-free 0.249 |
| 9JIR Crystal structure of V30M-TTR in complex with ioxynil Deposited 2024-09-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | A1L37 ioxynil × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1 M NaOAc pH 4.6
|
Resolution 1.30 Å R-free 0.197 |
| 9JIS Crystal structure of V30M-TTR in complex with aclonifen Deposited 2024-09-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
|
Mutation：V30M Mutation：V30M | A1L38 Aclonifen × 4 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1 M NaOAc pH 4.6
|
Resolution 1.41 Å R-free 0.189 |
| 9NNN Cryo-EM structure of amyloid fibril extracted from the heart of a variant ATTR D38A amyloidosis patient Deposited 2025-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；fibrils were eluted in ice-cold water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å |
| 9PX6 ATTR cardiac amyloid fibrils apex1 Deposited 2025-08-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
Chain F
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å |
| 9PX7 ATTR cardiac amyloid fibrils apex2 Deposited 2025-08-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
Chain F
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 9PX9 ATTR V122I cardiac amyloid fibrils Deposited 2025-08-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
1–147（147 aa）
Chain B
1–147（147 aa）
Chain C
1–147（147 aa）
Chain D
1–147（147 aa）
Chain E
1–147（147 aa）
Chain F
1–147（147 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å |
| 9RGK Human Transthyretin I107V Mutant Deposited 2025-06-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
|
Mutation：I107V Mutation：I107V | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2M (NH4)2SO4; 100 mM citrate buffer pH 5.5; 7 v/v % glycerol
|
Resolution 1.70 Å R-free 0.217 |
| 9RSP Cryogenic crystal structure of the perdeuterated TTR mutant V30M at pH5. Deposited 2025-07-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；1.7 M Sodium Malonate pH 5
|
Resolution 1.61 Å R-free 0.201 |
| 9RSR Cryogenic crystal structure of the TTR mutant V30M at pH5. Deposited 2025-07-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；2.15 M sodium malonate pH 5
|
Resolution 1.25 Å R-free 0.209 |
| 9RTO Room temperature crystal structure of the perdeuterated TTR mutant V30M at pH5. Deposited 2025-07-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
30–144（115 aa）
Chain B
30–144（115 aa）
|
Mutation：V30M Mutation：V30M | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；1.7 M sodium malonate pH5
|
Resolution 1.56 Å R-free 0.198 |
| 9WPB Crystal structure of human transthyretin (TTR) with pryazole-based stabilizer Deposited 2025-09-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Not recorded | A1MB7 4-[2-[3,5-bis(chloranyl)-1~{H}-pyrazol-4-yl]ethyl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2M CaCl2, 20% w/v PEG 3350
|
Resolution 1.58 Å R-free 0.180 |
| 9WPB Crystal structure of human transthyretin (TTR) with pryazole-based stabilizer Deposited 2025-09-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
21–147（127 aa）
Chain F
21–147（127 aa）
Chain G
21–147（127 aa）
Chain H
21–147（127 aa）
|
Not recorded | A1MB7 4-[2-[3,5-bis(chloranyl)-1~{H}-pyrazol-4-yl]ethyl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2M CaCl2, 20% w/v PEG 3350
|
Resolution 1.58 Å R-free 0.180 |
| 9ZBV Human TTR-C10A at pH 7.4 Deposited 2025-11-21 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
|
Mutation：C10A Mutation：C10A Mutation：C10A Mutation：C10A | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å |
| 9ZLD Cryo-EM structure of hepatic amyloid fibril from a variant ATTRV122delta, single filament morphology Deposited 2025-12-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric |
Chain A
21–147（127 aa）
Chain B
21–147（127 aa）
Chain C
21–147（127 aa）
Chain D
21–147（127 aa）
Chain E
21–147（127 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7；ice-chilled water
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å |
460 other PDB entries and 501 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | TTHY_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 13–159； UniProt 1–147 Author chain B； PDBConstruct 13–159； UniProt 1–147 |
